Details of the Drug Combinations

General Information of This Drug (ID: DMNO38U)

Drug Name
Bortezomib   DMNO38U
Synonyms
179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
Indication
Disease Entry ICD 11 Status REF
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Lymphoproliferative syndrome N.A. Approved [1]
MALT lymphoma N.A. Approved [1]
Mantle cell lymphoma 2A85.5 Approved [2]
Minimally invasive lung adenocarcinoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [3]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Non-hodgkin lymphoma 2B33.5 Phase 3 [3]
B-cell neoplasm N.A. Investigative [1]
Colon cancer 2B90.Z Investigative [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1114 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole + Bortezomib DCCE1PI 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
10-hydroxycamptothecin + Bortezomib DCRK54K 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [5]
10-hydroxycamptothecin + Bortezomib DCFK1RX 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [6]
10-hydroxycamptothecin + Bortezomib DCE3AXA 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A549) [6]
10-hydroxycamptothecin + Bortezomib DC9SBLB 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HCT116) [6]
10-hydroxycamptothecin + Bortezomib DCS2K45 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: M14) [6]
10-hydroxycamptothecin + Bortezomib DCS9XJQ 10-hydroxycamptothecin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
10-hydroxycamptothecin + Bortezomib DCFAV0W 10-hydroxycamptothecin Hodgkin lymphoma (Cell Line: L-1236) [6]
10-hydroxycamptothecin + Bortezomib DCASIEE 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [6]
Abacavir + Bortezomib DC8AA45 Abacavir Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
ABIRATERONE + Bortezomib DCGFSHC ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
ABIRATERONE + Bortezomib DCEK6SH ABIRATERONE Anaplastic large cell lymphoma (Cell Line: SR) [4]
ABIRATERONE + Bortezomib DC4DUS7 ABIRATERONE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
ABIRATERONE + Bortezomib DCTOLGT ABIRATERONE Glioma (Cell Line: SF-268) [4]
ABIRATERONE + Bortezomib DCEHA35 ABIRATERONE Adenocarcinoma (Cell Line: HT29) [6]
ABIRATERONE + Bortezomib DCXDZ86 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Acamprosate + Bortezomib DC57KL4 Acamprosate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Acetohexamide + Bortezomib DC7LH5O Acetohexamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Amantadine + Bortezomib DCE0K1P Amantadine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Amodiaquine + Bortezomib DCC199A Amodiaquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Amonafide + Bortezomib DCL05OX Amonafide Adenocarcinoma (Cell Line: A549) [4]
Amonafide + Bortezomib DCV55EH Amonafide Adenocarcinoma (Cell Line: HT29) [4]
Amonafide + Bortezomib DCR600T Amonafide Adenocarcinoma (Cell Line: HCC-2998) [4]
Amonafide + Bortezomib DC0V3X9 Amonafide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Amonafide + Bortezomib DCVAIZ1 Amonafide Colon adenocarcinoma (Cell Line: COLO 205) [5]
Anamorelin + Bortezomib DCDQOS4 Anamorelin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Anastrozole + Bortezomib DCM9YOR Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Anastrozole + Bortezomib DCIJJT0 Anastrozole Amelanotic melanoma (Cell Line: M14) [4]
Anastrozole + Bortezomib DCJMQTO Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Anastrozole + Bortezomib DCLUUJ5 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Anastrozole + Bortezomib DCWX6KG Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Anastrozole + Bortezomib DC8BFXL Anastrozole Malignant melanoma (Cell Line: UACC62) [4]
Anastrozole + Bortezomib DC9HNXQ Anastrozole Melanoma (Cell Line: UACC-257) [4]
Anastrozole + Bortezomib DCFY4TL Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Anastrozole + Bortezomib DCLDR8U Anastrozole Carcinoma (Cell Line: MCF7) [5]
Arfolitixorin + Bortezomib DCOUXMY Arfolitixorin Glioma (Cell Line: SF-295) [4]
Arfolitixorin + Bortezomib DCDV9LV Arfolitixorin Adenocarcinoma (Cell Line: A549) [6]
Artemisinin + Bortezomib DCASH2E Artemisinin DD2 (Cell Line: DD2) [4]
Asenapine + Bortezomib DCZIFHG Asenapine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Auranofin + Bortezomib DCH8RJF Auranofin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Azathioprine + Bortezomib DCILR4V Azathioprine Hodgkin lymphoma (Cell Line: L-1236) [4]
Bendamustine hydrochloride + Bortezomib DCT0J5Q Bendamustine hydrochloride Colon adenocarcinoma (Cell Line: COLO 205) [5]
Bendamustine hydrochloride + Bortezomib DCSZ0OK Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bendamustine hydrochloride + Bortezomib DCKJVSO Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Benserazide + Bortezomib DCFTES2 Benserazide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
BHV-0223 + Bortezomib DCJ45CG BHV-0223 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
BIO-300 + Bortezomib DCTHK7J BIO-300 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
BIO-300 + Bortezomib DCMOWA4 BIO-300 Carcinoma (Cell Line: MCF7) [5]
BIO-300 + Bortezomib DCTZOEG BIO-300 Colon carcinoma (Cell Line: KM12) [5]
BIO-300 + Bortezomib DCU17JE BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [6]
BIO-300 + Bortezomib DCXLV26 BIO-300 Adenocarcinoma (Cell Line: A549) [6]
BIO-300 + Bortezomib DCRMZIA BIO-300 Adenocarcinoma (Cell Line: HT29) [6]
BIO-300 + Bortezomib DCEYLUJ BIO-300 Malignant melanoma (Cell Line: UACC62) [6]
BIO-300 + Bortezomib DCAXV8X BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Bleomycin + Bortezomib DC77QF1 Bleomycin Astrocytoma (Cell Line: U251) [4]
Bleomycin + Bortezomib DCXY3DJ Bleomycin Astrocytoma (Cell Line: SNB-19) [4]
Bleomycin + Bortezomib DC45MAY Bleomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Bleomycin + Bortezomib DCIIBTB Bleomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Bleomycin + Bortezomib DCMDM00 Bleomycin Glioma (Cell Line: SF-539) [4]
Bleomycin + Bortezomib DCW8IZU Bleomycin Glioma (Cell Line: SF-295) [4]
Bleomycin + Bortezomib DC448BD Bleomycin Glioma (Cell Line: SF-268) [4]
Bleomycin + Bortezomib DC25USS Bleomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Bleomycin + Bortezomib DCMX9TW Bleomycin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Bleomycin + Bortezomib DCCXXHB Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Bleomycin + Bortezomib DCROSG4 Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Bleomycin + Bortezomib DCYKZ8B Bleomycin Adenocarcinoma (Cell Line: OVCAR3) [6]
Bleomycin + Bortezomib DC1VU2P Bleomycin Adenocarcinoma (Cell Line: A549) [6]
Bleomycin + Bortezomib DCCYM7P Bleomycin Adenocarcinoma (Cell Line: HT29) [6]
Bleomycin + Bortezomib DCKMGIG Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Bleomycin + Bortezomib DCDNZ4K Bleomycin Adenocarcinoma (Cell Line: SW-620) [6]
Bleomycin + Bortezomib DCPCBKN Bleomycin Amelanotic melanoma (Cell Line: M14) [6]
Bleomycin + Bortezomib DC3Z9MB Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Bleomycin + Bortezomib DCSHPSF Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Bleomycin + Bortezomib DCJ68XO Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Bleomycin + Bortezomib DC3PU3I Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Bleomycin + Bortezomib DCX3AGK Bleomycin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Bleomycin + Bortezomib DC9MNK6 Bleomycin Malignant melanoma (Cell Line: UACC62) [6]
Bleomycin + Bortezomib DCZFGUK Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Bleomycin + Bortezomib DCOLXRJ Bleomycin Melanoma (Cell Line: UACC-257) [6]
Bleomycin + Bortezomib DCXYPKE Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Bleomycin + Bortezomib DCK7YNE Bleomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Bortezomib + Aprepitant DCMNO4G Aprepitant Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Meclofenamic acid DC8XXV0 Meclofenamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ribavirin-TP DCYGIXH Ribavirin-TP Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mebutamate DCD5LYX Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Baclofen DCNLYV5 Baclofen Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Bepridil DC0VEIK Bepridil Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Triiodothyronine DCLCBWL Triiodothyronine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Gefitinib DCIM3TH Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Acetazolamide DCZCD9Z Acetazolamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Paromomycin DC5B671 Paromomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ruxolitinib DCKQGQM Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [4]
Bortezomib + Kanamycin DCIPQZ2 Kanamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Imipramine DCH3HYX Imipramine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Furazolidone DCV5C9S Furazolidone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Chlorphenesin DCLL0OS Chlorphenesin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + GYKI-52466 DCUUZEP GYKI-52466 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + PMID28460551-Compound-2 DCZMU2D PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Tacrine DCLSSXO Tacrine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Panobinostat DCPZNA5 Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Bortezomib + Methotrexate DCHMJWR Methotrexate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Dihydroergotamine DCG0Y31 Dihydroergotamine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Repaglinide DC4J2HO Repaglinide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mephenytoin DCKKHPF Mephenytoin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Arsenic trioxide DCOJ7RH Arsenic trioxide Adenocarcinoma (Cell Line: A549) [4]
Bortezomib + Arsenic trioxide DC5H25W Arsenic trioxide Adenocarcinoma (Cell Line: NCIH23) [4]
Bortezomib + Arsenic trioxide DCTEXTR Arsenic trioxide Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + Arsenic trioxide DCFRGCQ Arsenic trioxide Astrocytoma (Cell Line: U251) [4]
Bortezomib + Arsenic trioxide DC6DEBR Arsenic trioxide Astrocytoma (Cell Line: SNB-19) [4]
Bortezomib + Arsenic trioxide DCCSUTB Arsenic trioxide Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + Arsenic trioxide DCWQ15M Arsenic trioxide Melanoma (Cell Line: UACC-257) [4]
Bortezomib + Arsenic trioxide DCKBIU2 Arsenic trioxide Melanoma (Cell Line: SK-MEL-2) [4]
Bortezomib + Arsenic trioxide DCA36C5 Arsenic trioxide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Bortezomib + Arsenic trioxide DCGHFRL Arsenic trioxide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Bortezomib + Arsenic trioxide DCNQWXX Arsenic trioxide Prostate carcinoma (Cell Line: PC-3) [4]
Bortezomib + Arsenic trioxide DCDJ6SM Arsenic trioxide Renal cell carcinoma (Cell Line: SN12C) [4]
Bortezomib + RTB101 DC0L8U7 RTB101 Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + RTB101 DCBK8GA RTB101 Adenocarcinoma (Cell Line: OVCAR3) [4]
Bortezomib + RTB101 DCSFTSC RTB101 Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + RTB101 DCLY76B RTB101 Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + RTB101 DC2L65Q RTB101 Adenocarcinoma (Cell Line: NCIH23) [4]
Bortezomib + RTB101 DCPLSK1 RTB101 Adenocarcinoma (Cell Line: NCIH520) [4]
Bortezomib + RTB101 DCNM42Y RTB101 Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + RTB101 DCAQPN8 RTB101 Adenocarcinoma (Cell Line: DLD1) [4]
Bortezomib + RTB101 DCQPRDL RTB101 Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + RTB101 DCIAOKW RTB101 Adenocarcinoma (Cell Line: HT29) [4]
Bortezomib + RTB101 DC3G3GI RTB101 Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + RTB101 DCT1GE7 RTB101 Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + RTB101 DCYDPE0 RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + RTB101 DCVWF3Q RTB101 Germ cell tumour (Cell Line: PA1) [4]
Bortezomib + RTB101 DCFFVJJ RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + RTB101 DCJNC0Q RTB101 Malignant melanoma (Cell Line: A375) [4]
Bortezomib + RTB101 DCY31ZI RTB101 Malignant melanoma (Cell Line: HT144) [4]
Bortezomib + RTB101 DCIT67R RTB101 Malignant melanoma (Cell Line: RPMI7951) [4]
Bortezomib + RTB101 DC2CZ8K RTB101 Malignant melanoma (Cell Line: SKMEL30) [4]
Bortezomib + RTB101 DCW0A6Z RTB101 Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + RTB101 DCSZE8Y RTB101 Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + RTB101 DCJL801 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + RTB101 DCI62GE RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + RTB101 DC04K35 RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Bortezomib + RTB101 DC01W81 RTB101 Prostate carcinoma (Cell Line: LNCAP) [4]
Bortezomib + RTB101 DCDWELD RTB101 Prostate carcinoma (Cell Line: VCAP) [4]
Bortezomib + SCH-900776 DC0X7LK SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [4]
Bortezomib + SCH-900776 DCPF8O1 SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + SCH-900776 DCDSJ6X SCH-900776 Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + SCH-900776 DCODT70 SCH-900776 Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + SCH-900776 DCB4552 SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + SCH-900776 DC8YRTY SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + Pazopanib HCl DC7ZNF3 Pazopanib HCl Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ezetimibe DCQJPS1 Ezetimibe Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Plicamycin DCUDL5E Plicamycin Hodgkin lymphoma (Cell Line: L-1236) [4]
Bortezomib + Testosterone DCYZWG5 Testosterone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Acitretin DCCGGLT Acitretin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Pepstatin DCAM9DF Pepstatin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + 10-hydroxycamptothecin DCYXJ5R 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + 10-hydroxycamptothecin DC7OLQ0 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + 10-hydroxycamptothecin DCKSUGC 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + 10-hydroxycamptothecin DCRGVJO 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + 10-hydroxycamptothecin DCPZVWM 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [4]
Bortezomib + 10-hydroxycamptothecin DC3BT5J 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + 10-hydroxycamptothecin DCYH91F 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + 10-hydroxycamptothecin DCRON4K 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + 10-hydroxycamptothecin DC6JFIA 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + 10-hydroxycamptothecin DCI759X 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [4]
Bortezomib + 10-hydroxycamptothecin DC7VHPJ 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + 10-hydroxycamptothecin DCCG7BS 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [4]
Bortezomib + 10-hydroxycamptothecin DC6QTWC 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [4]
Bortezomib + 10-hydroxycamptothecin DCY0S5J 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + 10-hydroxycamptothecin DCNU0LJ 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + 10-hydroxycamptothecin DCO63PK 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + 10-hydroxycamptothecin DCYE72I 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Bortezomib + 10-hydroxycamptothecin DCT4N3E 10-hydroxycamptothecin Prostate carcinoma (Cell Line: LNCAP) [4]
Bortezomib + IT-141 DC13ZO3 IT-141 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + SNX-2112 DCPDLA3 SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + SNX-2112 DCYRXX7 SNX-2112 Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + SNX-2112 DC23XPG SNX-2112 Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + SNX-2112 DCZ2625 SNX-2112 Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + SNX-2112 DC9SKKO SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + SNX-2112 DCVBWA5 SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + SNX-2112 DC8CTAY SNX-2112 Malignant melanoma (Cell Line: A375) [4]
Bortezomib + SNX-2112 DCGLYDT SNX-2112 Malignant melanoma (Cell Line: HT144) [4]
Bortezomib + SNX-2112 DCUXD43 SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [4]
Bortezomib + SNX-2112 DC2OXO2 SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [4]
Bortezomib + SNX-2112 DCLVMI6 SNX-2112 Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + SNX-2112 DCNZ0X4 SNX-2112 Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + SNX-2112 DC6GD9N SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + SNX-2112 DCGIMUE SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + SNX-2112 DC47O1L SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Bortezomib + Methylergonovine DC5EPS8 Methylergonovine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Palonosetron DCGCC6T Palonosetron Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Isosorbide dinitrate DC1Y5Y7 Isosorbide dinitrate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Buspirone DCH055K Buspirone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Terameprocol DC2D3Y2 Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + SCH 727965 DCBW8C1 SCH 727965 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ursodeoxycholic acid DC7JYHL Ursodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + ETHISTERONE DCURW11 ETHISTERONE Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cilastatin DCOD46I Cilastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + LY03004 DCU0C75 LY03004 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Aminosalicylic acid DC4RNAU Aminosalicylic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Fibrates DC6TP4J Fibrates Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + VR-776 DCSKO89 VR-776 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ciprofibrate DCJ7NW5 Ciprofibrate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mecamylamine DCCFPVO Mecamylamine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + PHA-739358 DCUKELO PHA-739358 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mitomycin DC7F94O Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Bortezomib + Naringenin DCZWUFL Naringenin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Tolazoline DCQAPPG Tolazoline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Procarbazine DCIDSTK Procarbazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Bosentan DCHFDZO Bosentan Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Sulfapyridine DCDQ1QU Sulfapyridine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Arfolitixorin DC886XR Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Niclosamide DCW3V27 Niclosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Eflornithine DC0I0BU Eflornithine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Norcisapride DC1ZZ4Z Norcisapride Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Etonogestrel DCKZLZR Etonogestrel Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Trifluoperazine DCNC9RM Trifluoperazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Oseltamivir DCTIGFF Oseltamivir Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ibutilide DCT9VT1 Ibutilide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Fenoprofen DC2S921 Fenoprofen Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Tamoxifen DCO8DZL Tamoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ridaforolimus DCHNK71 Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + Ridaforolimus DC0JJED Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + Ridaforolimus DCLGER4 Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Ridaforolimus DCPHVWI Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + Allopurinol DCQPI3W Allopurinol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + MK-4827 DCZ7PRA MK-4827 Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + MK-4827 DCBEMGI MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [4]
Bortezomib + MK-4827 DCXG1XH MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + MK-4827 DC2KTZ8 MK-4827 Adenocarcinoma (Cell Line: NCIH23) [4]
Bortezomib + MK-4827 DCXLGL9 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [4]
Bortezomib + MK-4827 DC9UUY5 MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + MK-4827 DCTG1E3 MK-4827 Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + MK-4827 DCWGFDK MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + MK-4827 DCSM0Q6 MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + MK-4827 DC1MOB9 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [4]
Bortezomib + MK-4827 DC7PA1E MK-4827 Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + MK-4827 DCYID6P MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + MK-4827 DCM8IQH MK-4827 Prostate carcinoma (Cell Line: LNCAP) [4]
Bortezomib + Idarubicin DCEJVXK Idarubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Idarubicin DC58HZM Idarubicin Glioblastoma? (Cell Line: T98G) [4]
Bortezomib + Probenecid DC87PC2 Probenecid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Lomustine DCYY4GB Lomustine Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + Lomustine DCIHAP2 Lomustine Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + Lomustine DCMNL2M Lomustine Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + Lomustine DCY1X2A Lomustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Lomustine DC1Y3K4 Lomustine Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + Lomustine DCPMEH5 Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + Atenolol DC5CTSE Atenolol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Linagliptin DCZIOAT Linagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Pramipexole DCUUMVA Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Methylene blue DCV64VI Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mebendazole DCVOZ3F Mebendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ethinyl estradiol DCN6ELX Ethinyl estradiol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mesalazine DCC5UL2 Mesalazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Moricizine DCZ6324 Moricizine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Topotecan DCM27H8 Topotecan Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + GSK525762 DCDCXUV GSK525762 Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + Olanzapine DCE3Q48 Olanzapine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Clascoterone DCSP2BU Clascoterone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Dopamine DCN14GT Dopamine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cefmenoxime DCHN9TH Cefmenoxime Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Trimethobenzamide DC3J6NS Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Maprotiline DCNTWA5 Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Eptifibatide DC8LYOI Eptifibatide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ethambutol DC0UWM6 Ethambutol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Leflunomide DCHBU6I Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cisplatin DC53QUT Cisplatin Adenocarcinoma (Cell Line: A549) [4]
Bortezomib + Cisplatin DCDAUYD Cisplatin Glioma (Cell Line: SF-539) [4]
Bortezomib + Cisplatin DCL8YUB Cisplatin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Bortezomib + Cisplatin DCGHCWD Cisplatin Melanoma (Cell Line: MALME-3M) [4]
Bortezomib + Cisplatin DCFORLO Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Bortezomib + Cisplatin DCD9KC6 Cisplatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Bortezomib + Chlorambucil DCCD8ER Chlorambucil Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Amiloride DCAANGJ Amiloride Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Bumetanide DC851GV Bumetanide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Sorafenib DCHWOJS Sorafenib Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + Sorafenib DC90NR6 Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + Sorafenib DCBKZWF Sorafenib Adenocarcinoma (Cell Line: NCIH520) [4]
Bortezomib + Sorafenib DC6F7F2 Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + Sorafenib DCYI986 Sorafenib Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + Sorafenib DCGV1QM Sorafenib Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + Sorafenib DCBIHT8 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Sorafenib DCZU03K Sorafenib Germ cell tumour (Cell Line: PA1) [4]
Bortezomib + Sorafenib DC876V3 Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + Sorafenib DCZULYZ Sorafenib Malignant melanoma (Cell Line: A375) [4]
Bortezomib + Sorafenib DCSID7E Sorafenib Malignant melanoma (Cell Line: HT144) [4]
Bortezomib + Sorafenib DC88IIV Sorafenib Malignant melanoma (Cell Line: SKMEL30) [4]
Bortezomib + Sorafenib DCIKOHY Sorafenib Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + Sorafenib DCBWRBC Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + Sorafenib DCZE21S Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + Sorafenib DCULGX1 Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Bortezomib + Sorafenib DCFMMCE Sorafenib Prostate carcinoma (Cell Line: LNCAP) [4]
Bortezomib + Chloroquine DC29HJY Chloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Hyodeoxycholic acid DCOHDN2 Hyodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Asenapine DCVFPWW Asenapine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Quinine DCYS183 Quinine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Pomalidomide DCFCRRX Pomalidomide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Spironolactone DCR2TV8 Spironolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Maraviroc DCK2432 Maraviroc Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Chlormezanone DCXEDNT Chlormezanone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mycophenolic acid DCGN361 Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cisatracurium DC3L0KT Cisatracurium Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Mefloquine DCOBNMX Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Pizotyline DC5BTSJ Pizotyline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Doxorubicin DCWUB33 Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Iloprost DCKO2FD Iloprost Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Zileuton DCPPJG4 Zileuton Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Silver sulfadiazine DCNTIGJ Silver sulfadiazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Testolactone DC8CNZR Testolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Sumatriptan DC2X710 Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Olmesartan medoxomil DCKSPMZ Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + FORMESTANE DC0V9YI FORMESTANE Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Vorinostat DCACME0 Vorinostat Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + Vorinostat DCF6N18 Vorinostat Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + Vorinostat DC2LOPD Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + Vorinostat DC2UQYS Vorinostat Adenocarcinoma (Cell Line: NCIH23) [4]
Bortezomib + Vorinostat DCXCL67 Vorinostat Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + Vorinostat DC68Z2P Vorinostat Adenocarcinoma (Cell Line: DLD1) [4]
Bortezomib + Vorinostat DCUCH22 Vorinostat Adenocarcinoma (Cell Line: HCT116) [4]
Bortezomib + Vorinostat DC5WV1A Vorinostat Adenocarcinoma (Cell Line: SW-620) [4]
Bortezomib + Vorinostat DCY53QC Vorinostat Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Vorinostat DCKC8LQ Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Vorinostat DC7IVT5 Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + Vorinostat DC9RE1J Vorinostat Malignant melanoma (Cell Line: HT144) [4]
Bortezomib + Vorinostat DC9SL68 Vorinostat Malignant melanoma (Cell Line: RPMI7951) [4]
Bortezomib + Vorinostat DC7P8CQ Vorinostat Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + Vorinostat DCPE0YC Vorinostat Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + Vorinostat DC4I2QW Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + Vorinostat DCQ44HW Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Bortezomib + Estramustine DC220WM Estramustine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cerivastatin DCECXOV Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + BGT226 DCPD5QX BGT226 Hodgkin lymphoma (Cell Line: L-1236) [4]
Bortezomib + Metaxalone DC51WFI Metaxalone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Busulfan DC6L5B4 Busulfan Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Atovaquone DCVVSYB Atovaquone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Acetohydroxamic Acid DC1KD22 Acetohydroxamic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Albendazole DC30PG1 Albendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Ibrutinib DCP3W8D Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Bortezomib + GSK2194069 DCOZI6D GSK2194069 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Dasatinib DCZUWRL Dasatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Bortezomib + Dasatinib DCZTWDQ Dasatinib Adenocarcinoma (Cell Line: A427) [4]
Bortezomib + Dasatinib DCCYDK6 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Bortezomib + Dasatinib DCY5FDU Dasatinib Adenocarcinoma (Cell Line: DLD1) [4]
Bortezomib + Dasatinib DC2WW9S Dasatinib Adenocarcinoma (Cell Line: HT29) [4]
Bortezomib + Dasatinib DCR483O Dasatinib Amelanotic melanoma (Cell Line: A2058) [4]
Bortezomib + Dasatinib DCTIYBF Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Dasatinib DCAY03H Dasatinib Germ cell tumour (Cell Line: PA1) [4]
Bortezomib + Dasatinib DCF4AZD Dasatinib Malignant melanoma (Cell Line: A375) [4]
Bortezomib + Dasatinib DCUJNZ5 Dasatinib Malignant melanoma (Cell Line: UACC62) [4]
Bortezomib + Dasatinib DCXR7TG Dasatinib Mesothelioma (Cell Line: MSTO) [4]
Bortezomib + Dasatinib DC7F6QB Dasatinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Bortezomib + Dasatinib DC6B4RU Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Bortezomib + Cytarabine DCC3B9L Cytarabine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Cilostazol DCXQFSQ Cilostazol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Bortezomib + Arsenic trioxide DCFRY7M Arsenic trioxide Colon adenocarcinoma (Cell Line: COLO 205) [5]
Bortezomib + RTB101 DC60SB8 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Bortezomib + RTB101 DCVG3CX RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Bortezomib + RTB101 DCUOTZ1 RTB101 Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + RTB101 DCAHAV2 RTB101 Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + RTB101 DCNBMYM RTB101 Breast carcinoma (Cell Line: OCUBM) [5]
Bortezomib + RTB101 DC4KIQ9 RTB101 Carcinoma (Cell Line: OV90) [5]
Bortezomib + RTB101 DC5RG3Q RTB101 Carcinoma (Cell Line: EFM192B) [5]
Bortezomib + RTB101 DC7M6BR RTB101 Carcinoma (Cell Line: MDAMB436) [5]
Bortezomib + RTB101 DCXXIF4 RTB101 Colon adenocarcinoma (Cell Line: LOVO) [5]
Bortezomib + RTB101 DC3U8LH RTB101 Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + RTB101 DCOQ701 RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bortezomib + RTB101 DCWEEOM RTB101 Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + 10-hydroxycamptothecin DC2CW60 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Bortezomib + 10-hydroxycamptothecin DC8H1UD 10-hydroxycamptothecin Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + 10-hydroxycamptothecin DCVHMJ7 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + 10-hydroxycamptothecin DCFF5AO 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [5]
Bortezomib + 10-hydroxycamptothecin DC3CWEW 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [5]
Bortezomib + 10-hydroxycamptothecin DC5RIIZ 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + 10-hydroxycamptothecin DC97LID 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bortezomib + 10-hydroxycamptothecin DC8BQL9 10-hydroxycamptothecin Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + SNX-2112 DC6Y2YR SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [5]
Bortezomib + SNX-2112 DC5LXNE SNX-2112 Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + Ridaforolimus DCU6ET4 Ridaforolimus Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + Ridaforolimus DCP4R3D Ridaforolimus Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + MK-4827 DC2TGAA MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Bortezomib + MK-4827 DCG57DL MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Bortezomib + MK-4827 DC0AGCJ MK-4827 Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + MK-4827 DC3R9L4 MK-4827 Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + MK-4827 DCFCVHI MK-4827 Breast carcinoma (Cell Line: OCUBM) [5]
Bortezomib + MK-4827 DCN1GAR MK-4827 Carcinoma (Cell Line: OV90) [5]
Bortezomib + MK-4827 DCT2OFU MK-4827 Carcinoma (Cell Line: EFM192B) [5]
Bortezomib + MK-4827 DC333HS MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [5]
Bortezomib + MK-4827 DCJL3TB MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bortezomib + MK-4827 DCYVMM0 MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + Lomustine DCPBG0K Lomustine Carcinoma (Cell Line: EFM192B) [5]
Bortezomib + Lomustine DCD3TSX Lomustine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Bortezomib + Lomustine DCJ2T3M Lomustine Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + GSK525762 DC4GDPH GSK525762 Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + GSK525762 DCOVNX2 GSK525762 Carcinoma (Cell Line: MDAMB436) [5]
Bortezomib + GSK525762 DC32K0A GSK525762 Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + GSK525762 DCGO5LT GSK525762 Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + Sorafenib DCF66VG Sorafenib Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + Sorafenib DC09GZD Sorafenib Breast carcinoma (Cell Line: OCUBM) [5]
Bortezomib + Sorafenib DCD7AFQ Sorafenib Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + Sorafenib DCUCMG9 Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + Vorinostat DCE4KV4 Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Bortezomib + Vorinostat DCRZZSW Vorinostat Carcinoma (Cell Line: OV90) [5]
Bortezomib + Vorinostat DCVZZIX Vorinostat Carcinoma (Cell Line: EFM192B) [5]
Bortezomib + Vorinostat DC4NZYP Vorinostat Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + Vorinostat DCKMBWA Vorinostat Rectal adenocarcinoma (Cell Line: SW837) [5]
Bortezomib + Dasatinib DC5UFKH Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Bortezomib + Dasatinib DCHN51N Dasatinib Breast carcinoma (Cell Line: ZR751) [5]
Bortezomib + Dasatinib DCAK9FB Dasatinib Breast carcinoma (Cell Line: KPL1) [5]
Bortezomib + Dasatinib DC7KDDE Dasatinib Breast carcinoma (Cell Line: OCUBM) [5]
Bortezomib + Dasatinib DCJQYPB Dasatinib Carcinoma (Cell Line: MDAMB436) [5]
Bortezomib + Dasatinib DCB2I2X Dasatinib Colon adenocarcinoma (Cell Line: LOVO) [5]
Bortezomib + Dasatinib DCERSH1 Dasatinib Colon carcinoma (Cell Line: RKO) [5]
Bortezomib + Dasatinib DCXPHMD Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [5]
Brincidofovir + Bortezomib DCAJIHZ Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Cabazitaxel + Bortezomib DCO8EJ4 Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [4]
Cabazitaxel + Bortezomib DCW9WSH Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Cabazitaxel + Bortezomib DCKS2LD Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [4]
Cabazitaxel + Bortezomib DCKL8CZ Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Cabazitaxel + Bortezomib DCPMK2F Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [4]
Cabazitaxel + Bortezomib DCM95NA Cabazitaxel Glioma (Cell Line: SF-539) [4]
Cabazitaxel + Bortezomib DCCTSRL Cabazitaxel Glioma (Cell Line: SF-295) [4]
Cabazitaxel + Bortezomib DC9UF4K Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Cabazitaxel + Bortezomib DC74QA3 Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Cabazitaxel + Bortezomib DC1YKX4 Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [4]
Cabazitaxel + Bortezomib DCA7W4D Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Cabazitaxel + Bortezomib DCLCRC4 Cabazitaxel Malignant melanoma (Cell Line: UACC62) [4]
Cabazitaxel + Bortezomib DC3JDP9 Cabazitaxel Melanoma (Cell Line: UACC-257) [4]
Cabazitaxel + Bortezomib DCKYI5X Cabazitaxel Melanoma (Cell Line: MALME-3M) [4]
Cabazitaxel + Bortezomib DCX2AFJ Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Cabazitaxel + Bortezomib DCCCKE5 Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [4]
Cabazitaxel + Bortezomib DC0RFJ4 Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [4]
Cabazitaxel + Bortezomib DC268OW Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Cabazitaxel + Bortezomib DCD1A38 Cabazitaxel Carcinoma (Cell Line: RXF 393) [5]
Cabazitaxel + Bortezomib DC6ZMVS Cabazitaxel Carcinoma (Cell Line: MCF7) [5]
Cabazitaxel + Bortezomib DC2992E Cabazitaxel Colon adenocarcinoma (Cell Line: COLO 205) [5]
Cabazitaxel + Bortezomib DCKRR3I Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [5]
Chlorambucil + Bortezomib DCTB7OI Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Cinacalcet + Bortezomib DCNJGG9 Cinacalcet Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Clindamycin + Bortezomib DCLQ18H Clindamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Clopidogrel + Bortezomib DCGW3CE Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Crizotinib + Bortezomib DCFSMJE Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Crizotinib + Bortezomib DCVHQHI Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Crizotinib + Bortezomib DC016ZH Crizotinib Amelanotic melanoma (Cell Line: M14) [4]
Crizotinib + Bortezomib DCRWWH2 Crizotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Crizotinib + Bortezomib DC0UFUZ Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Crizotinib + Bortezomib DCLMATY Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Crizotinib + Bortezomib DC1H8MO Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Crizotinib + Bortezomib DCERUMO Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Crotamiton + Bortezomib DC4DR7G Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Cyclophosphamide + Bortezomib DCK0JWJ Cyclophosphamide Rectal adenocarcinoma (Cell Line: SW837) [5]
Dacarbazine + Bortezomib DCDCVYP Dacarbazine Adenocarcinoma (Cell Line: A549) [4]
Dacarbazine + Bortezomib DCNZA6D Dacarbazine Adenocarcinoma (Cell Line: NCIH23) [4]
Dacarbazine + Bortezomib DC728RN Dacarbazine Adenocarcinoma (Cell Line: HCT-15) [4]
Dacarbazine + Bortezomib DC0L0KP Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dacarbazine + Bortezomib DCIVMIV Dacarbazine Astrocytoma (Cell Line: U251) [4]
Dacarbazine + Bortezomib DCH4BJU Dacarbazine Astrocytoma (Cell Line: SNB-19) [4]
Dacarbazine + Bortezomib DC3VZ50 Dacarbazine Glioma (Cell Line: SF-295) [4]
Dacarbazine + Bortezomib DCM4D58 Dacarbazine Malignant melanoma (Cell Line: LOX IMVI) [4]
Dacarbazine + Bortezomib DCD9G8Y Dacarbazine Melanoma (Cell Line: UACC-257) [4]
Dacarbazine + Bortezomib DC4QKBZ Dacarbazine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Dacarbazine + Bortezomib DCL3KMS Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Dacarbazine + Bortezomib DCQBXBG Dacarbazine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Dactinomycin + Bortezomib DCAP4WS Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [6]
Dactinomycin + Bortezomib DC7FO9Z Dactinomycin Adenocarcinoma (Cell Line: HCT116) [6]
Dactinomycin + Bortezomib DCH60UF Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [6]
Dactinomycin + Bortezomib DCAIXZU Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Dactinomycin + Bortezomib DCU3LPG Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Dactinomycin + Bortezomib DCS9Z07 Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [6]
Dactinomycin + Bortezomib DCZPBJ2 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Dactinomycin + Bortezomib DCDI4SM Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Dasatinib + Bortezomib DCL93Y8 Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Dasatinib + Bortezomib DC03ANZ Dasatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Dasatinib + Bortezomib DCZM9PY Dasatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Dexamethasone + Bortezomib DC0GJLH Dexamethasone Breast carcinoma (Cell Line: KPL1) [5]
Dexamethasone + Bortezomib DCSECRO Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [6]
Dexrazoxane + Bortezomib DCV39FT Dexrazoxane Glioma (Cell Line: SF-268) [4]
Dexrazoxane + Bortezomib DCNZVC7 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [5]
Dexrazoxane + Bortezomib DCLKTMT Dexrazoxane Adenocarcinoma (Cell Line: A549) [6]
Dexrazoxane + Bortezomib DCE4WQQ Dexrazoxane Adenocarcinoma (Cell Line: HT29) [6]
Dexrazoxane + Bortezomib DCG5J2E Dexrazoxane Lung adenocarcinoma (Cell Line: HOP-62) [6]
Dichlorphenamide + Bortezomib DC5LBAM Dichlorphenamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Diethylcarbamazine + Bortezomib DCF4VX5 Diethylcarbamazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Digitoxin + Bortezomib DC17VAK Digitoxin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Digitoxin + Bortezomib DCZGZTM Digitoxin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Digitoxin + Bortezomib DC0LKUV Digitoxin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Diphenidol + Bortezomib DCZ2G8V Diphenidol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Doxorubicin + Bortezomib DCHVKYG Doxorubicin Adenocarcinoma (Cell Line: COLO320DM) [4]
Doxorubicin + Bortezomib DCQ9KHO Doxorubicin Amelanotic melanoma (Cell Line: A2058) [4]
Doxorubicin + Bortezomib DCCXR00 Doxorubicin Germ cell tumour (Cell Line: PA1) [4]
Doxorubicin + Bortezomib DCEMI5S Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Doxorubicin + Bortezomib DCD5RVT Doxorubicin Non small cell carcinoma (Cell Line: SKMES1) [4]
Doxorubicin + Bortezomib DCP1J99 Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Doxorubicin + Bortezomib DCZWWZ3 Doxorubicin Prostate carcinoma (Cell Line: LNCAP) [4]
Doxorubicin + Bortezomib DC7CYV2 Doxorubicin Prostate carcinoma (Cell Line: VCAP) [4]
Doxorubicin + Bortezomib DCI1EJ5 Doxorubicin Breast carcinoma (Cell Line: ZR751) [5]
Doxorubicin + Bortezomib DCDTAZY Doxorubicin Colon adenocarcinoma (Cell Line: LOVO) [5]
Doxorubicin + Bortezomib DCIUZI6 Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Doxorubicin + Bortezomib DC9RQWM Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [5]
Dronedarone + Bortezomib DCXT6AL Dronedarone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Efavirenz + Bortezomib DCUYRU3 Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Endoxifen + Bortezomib DCHNTJD Endoxifen Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Epirubicin + Bortezomib DCHXC2I Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Epirubicin + Bortezomib DCPNIBM Epirubicin Glioma (Cell Line: SF-268) [4]
Epirubicin + Bortezomib DCT9VGM Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Epirubicin + Bortezomib DCIR627 Epirubicin Adenocarcinoma (Cell Line: HT29) [6]
Epirubicin + Bortezomib DC9DWMV Epirubicin Amelanotic melanoma (Cell Line: M14) [6]
Epirubicin + Bortezomib DCXAQ0T Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Epirubicin + Bortezomib DCL1YI3 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Epirubicin + Bortezomib DCSXSW9 Epirubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Epirubicin + Bortezomib DCT6D8O Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Epirubicin + Bortezomib DC5A6FA Epirubicin Melanoma (Cell Line: SK-MEL-2) [6]
Epirubicin + Bortezomib DCY5I4O Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
ER819762 + Bortezomib DCII9H4 ER819762 Adenocarcinoma (Cell Line: HCC-2998) [6]
ER819762 + Bortezomib DCCQT0W ER819762 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
ER819762 + Bortezomib DC22G43 ER819762 Malignant melanoma (Cell Line: LOX IMVI) [6]
ER819762 + Bortezomib DCRDF5J ER819762 Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Erlotinib + Bortezomib DCSPRY5 Erlotinib Adenocarcinoma (Cell Line: CAOV3) [4]
Erlotinib + Bortezomib DCIMLCN Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Erlotinib + Bortezomib DCCGD91 Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Erlotinib + Bortezomib DCBTI3Z Erlotinib Adenocarcinoma (Cell Line: NCIH23) [4]
Erlotinib + Bortezomib DC4HGMW Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Erlotinib + Bortezomib DC7D6OW Erlotinib Adenocarcinoma (Cell Line: DLD1) [4]
Erlotinib + Bortezomib DCXJF7D Erlotinib Adenocarcinoma (Cell Line: HT29) [4]
Erlotinib + Bortezomib DCSGIP0 Erlotinib Adenocarcinoma (Cell Line: SW-620) [4]
Erlotinib + Bortezomib DCAU1WL Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Erlotinib + Bortezomib DCLZ968 Erlotinib Malignant melanoma (Cell Line: A375) [4]
Erlotinib + Bortezomib DCGQGN3 Erlotinib Malignant melanoma (Cell Line: RPMI7951) [4]
Erlotinib + Bortezomib DC9ARZ8 Erlotinib Malignant melanoma (Cell Line: SKMEL30) [4]
Erlotinib + Bortezomib DCLK0MH Erlotinib Mesothelioma (Cell Line: MSTO) [4]
Erlotinib + Bortezomib DC39SCU Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Erlotinib + Bortezomib DCXGXHG Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Erlotinib + Bortezomib DC322MJ Erlotinib Prostate carcinoma (Cell Line: VCAP) [4]
Erlotinib + Bortezomib DCHPRKQ Erlotinib Breast carcinoma (Cell Line: KPL1) [5]
Erlotinib + Bortezomib DCJSK1Y Erlotinib Carcinoma (Cell Line: OV90) [5]
Erlotinib + Bortezomib DC6XJ6D Erlotinib Carcinoma (Cell Line: EFM192B) [5]
Erlotinib + Bortezomib DC4BUJ0 Erlotinib Colon carcinoma (Cell Line: RKO) [5]
Erlotinib + Bortezomib DCCKS0O Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [5]
Estramustine + Bortezomib DCDPYGA Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Estramustine + Bortezomib DCWE0M0 Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Estramustine + Bortezomib DC6Z28G Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Estramustine + Bortezomib DCIQNI2 Estramustine Breast carcinoma (Cell Line: KPL1) [5]
Estramustine + Bortezomib DCS5JFC Estramustine Carcinoma (Cell Line: OV90) [5]
Estramustine + Bortezomib DCI30V1 Estramustine Carcinoma (Cell Line: EFM192B) [5]
Estramustine + Bortezomib DCQWP0C Estramustine Colon adenocarcinoma (Cell Line: LOVO) [5]
Estramustine + Bortezomib DCN180D Estramustine Colon carcinoma (Cell Line: KM12) [5]
Estramustine + Bortezomib DCLU3ND Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Estramustine + Bortezomib DCZMVI2 Estramustine Rectal adenocarcinoma (Cell Line: SW837) [5]
Estramustine + Bortezomib DCISVTS Estramustine Adenocarcinoma (Cell Line: COLO320DM) [6]
Estramustine + Bortezomib DC9E9NJ Estramustine Adenocarcinoma (Cell Line: DLD1) [6]
Estramustine + Bortezomib DC97OHD Estramustine Adenocarcinoma (Cell Line: SW-620) [6]
Estramustine + Bortezomib DCIO55I Estramustine Amelanotic melanoma (Cell Line: A2058) [6]
Estramustine + Bortezomib DCI6GEU Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Estramustine + Bortezomib DC4LZS1 Estramustine Malignant melanoma (Cell Line: HT144) [6]
Estramustine + Bortezomib DCFSUEA Estramustine Malignant melanoma (Cell Line: RPMI7951) [6]
Estramustine + Bortezomib DCHE1Q2 Estramustine Malignant melanoma (Cell Line: SKMEL30) [6]
Estramustine + Bortezomib DCZHRY6 Estramustine Malignant melanoma (Cell Line: UACC62) [6]
Estramustine + Bortezomib DC4YQYC Estramustine Mesothelioma (Cell Line: MSTO) [6]
Estramustine + Bortezomib DCE4P45 Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Ethinyl estradiol + Bortezomib DC1TX2T Ethinyl estradiol Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Etoposide + Bortezomib DC8ZHT9 Etoposide Adenocarcinoma (Cell Line: CAOV3) [4]
Etoposide + Bortezomib DCXB46N Etoposide Adenocarcinoma (Cell Line: NCIH2122) [4]
Etoposide + Bortezomib DCS0R4D Etoposide Adenocarcinoma (Cell Line: COLO320DM) [4]
Etoposide + Bortezomib DCHSVVQ Etoposide Adenocarcinoma (Cell Line: HT29) [4]
Etoposide + Bortezomib DC2L8YX Etoposide Amelanotic melanoma (Cell Line: A2058) [4]
Etoposide + Bortezomib DC6DFEM Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Etoposide + Bortezomib DCOJNE9 Etoposide Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Etoposide + Bortezomib DCSOGXX Etoposide Malignant melanoma (Cell Line: A375) [4]
Etoposide + Bortezomib DC1QAKG Etoposide Malignant melanoma (Cell Line: RPMI7951) [4]
Etoposide + Bortezomib DCQ7V0Y Etoposide Malignant melanoma (Cell Line: SKMEL30) [4]
Etoposide + Bortezomib DCDF7P0 Etoposide Mesothelioma (Cell Line: MSTO) [4]
Etoposide + Bortezomib DCQI2L4 Etoposide Non small cell carcinoma (Cell Line: SKMES1) [4]
Etoposide + Bortezomib DC0AN1M Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Etoposide + Bortezomib DC89GPI Etoposide Prostate carcinoma (Cell Line: LNCAP) [4]
Etoposide + Bortezomib DC2SMMZ Etoposide Breast carcinoma (Cell Line: ZR751) [5]
Etoposide + Bortezomib DCWCPFX Etoposide Colon adenocarcinoma (Cell Line: LOVO) [5]
Etoposide + Bortezomib DCLAO7B Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [5]
Flavonoid derivative 1 + Bortezomib DCIVNMR Flavonoid derivative 1 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Fludarabine + Bortezomib DC62M10 Fludarabine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Fludarabine + Bortezomib DCB26FE Fludarabine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Fludarabine + Bortezomib DCLJ0FN Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Fludarabine + Bortezomib DCGOFC6 Fludarabine Hodgkin lymphoma (Cell Line: L-1236) [6]
Fludarabine + Bortezomib DCYIUNH Fludarabine Lung adenocarcinoma (Cell Line: HOP-62) [6]
Fluorouracil + Bortezomib DC158YT Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Fluorouracil + Bortezomib DCLI7MH Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Fluorouracil + Bortezomib DCD2GP2 Fluorouracil Breast carcinoma (Cell Line: KPL1) [5]
Fluorouracil + Bortezomib DC2HOI2 Fluorouracil Carcinoma (Cell Line: OV90) [5]
Fluorouracil + Bortezomib DC3V4UM Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [5]
Fluorouracil + Bortezomib DCVVB74 Fluorouracil Colon carcinoma (Cell Line: RKO) [5]
Fluorouracil + Bortezomib DCJ0V7B Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fluorouracil + Bortezomib DCT8NSH Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [5]
Fluorouracil + Bortezomib DCZ205Z Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [6]
Fluorouracil + Bortezomib DC2TZE7 Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [6]
Fluorouracil + Bortezomib DC9BLAS Fluorouracil Adenocarcinoma (Cell Line: A427) [6]
Fluorouracil + Bortezomib DCLMC9Q Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [6]
Fluorouracil + Bortezomib DCNV7X6 Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [6]
Fluorouracil + Bortezomib DC04RGO Fluorouracil Adenocarcinoma (Cell Line: HT29) [6]
Fluorouracil + Bortezomib DCOCSVX Fluorouracil Adenocarcinoma (Cell Line: SW-620) [6]
Fluorouracil + Bortezomib DC62YJV Fluorouracil Amelanotic melanoma (Cell Line: A2058) [6]
Fluorouracil + Bortezomib DC1XZ4B Fluorouracil Germ cell tumour (Cell Line: PA1) [6]
Fluorouracil + Bortezomib DC6V07Q Fluorouracil Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Fluorouracil + Bortezomib DC4T49S Fluorouracil Malignant melanoma (Cell Line: A375) [6]
Fluorouracil + Bortezomib DC4AQBY Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [6]
Fluorouracil + Bortezomib DC438XI Fluorouracil Mesothelioma (Cell Line: MSTO) [6]
Fluorouracil + Bortezomib DCR0HFH Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [6]
Fluorouracil + Bortezomib DCLNO8W Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Fluorouracil + Bortezomib DCUR7DU Fluorouracil Prostate carcinoma (Cell Line: VCAP) [6]
Fluorouracil + Bortezomib DCLXNJX Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [6]
FORMESTANE + Bortezomib DCG4NQ7 FORMESTANE Glioma (Cell Line: SF-539) [4]
FORMESTANE + Bortezomib DCA06OF FORMESTANE Invasive ductal carcinoma (Cell Line: T-47D) [5]
Fulvestrant + Bortezomib DCMOIAW Fulvestrant Anaplastic large cell lymphoma (Cell Line: SR) [4]
Fulvestrant + Bortezomib DC9ANP3 Fulvestrant Colon adenocarcinoma (Cell Line: COLO 205) [5]
Fulvestrant + Bortezomib DCN5T0X Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [5]
Gefitinib + Bortezomib DCY3Y6T Gefitinib Adenocarcinoma (Cell Line: HT29) [4]
Gefitinib + Bortezomib DCHPNX9 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Gefitinib + Bortezomib DCDO39L Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Gefitinib + Bortezomib DCNYG76 Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Gemcitabine + Bortezomib DCMJ3WQ Gemcitabine Adenocarcinoma (Cell Line: CAOV3) [4]
Gemcitabine + Bortezomib DCJV837 Gemcitabine Adenocarcinoma (Cell Line: OVCAR3) [4]
Gemcitabine + Bortezomib DC0GUCT Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [4]
Gemcitabine + Bortezomib DC7CF5G Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [4]
Gemcitabine + Bortezomib DC60DXZ Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [4]
Gemcitabine + Bortezomib DC4TJVI Gemcitabine Adenocarcinoma (Cell Line: HT29) [4]
Gemcitabine + Bortezomib DCLNW5T Gemcitabine Amelanotic melanoma (Cell Line: A2058) [4]
Gemcitabine + Bortezomib DC7A53A Gemcitabine Malignant melanoma (Cell Line: RPMI7951) [4]
Gemcitabine + Bortezomib DC9SL2P Gemcitabine Mesothelioma (Cell Line: MSTO) [4]
Gemcitabine + Bortezomib DCOWWGT Gemcitabine Non small cell carcinoma (Cell Line: SKMES1) [4]
Gemcitabine + Bortezomib DC8XO78 Gemcitabine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Gemcitabine + Bortezomib DC1RSSH Gemcitabine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Gemcitabine + Bortezomib DCGQED7 Gemcitabine Carcinoma (Cell Line: MDAMB436) [5]
Gemcitabine + Bortezomib DC9NM8W Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [5]
GS4071 + Bortezomib DCL4LRX GS4071 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Guanfacine + Bortezomib DCCANGB Guanfacine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Hydroxychloroquine + Bortezomib DCYMPC7 Hydroxychloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Idarubicin + Bortezomib DCH90BO Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Idarubicin + Bortezomib DCW5PVP Idarubicin Carcinoma (Cell Line: OV90) [5]
Idarubicin + Bortezomib DCEPO2U Idarubicin Carcinoma (Cell Line: MDAMB436) [5]
Idarubicin + Bortezomib DCDVCWP Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [6]
Idarubicin + Bortezomib DCZ9CR9 Idarubicin Amelanotic melanoma (Cell Line: A2058) [6]
Idarubicin + Bortezomib DC4N1Y3 Idarubicin Mesothelioma (Cell Line: MSTO) [6]
Ifosfamide + Bortezomib DCQ6OJ6 Ifosfamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Ifosfamide + Bortezomib DCA44Z6 Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [4]
Ifosfamide + Bortezomib DCJP3OF Ifosfamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Imatinib + Bortezomib DCD10L7 Imatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Imatinib + Bortezomib DCFH5TB Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Imatinib + Bortezomib DCKTGXB Imatinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Indazole derivative 5 + Bortezomib DCB1SA7 Indazole derivative 5 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Indazole derivative 5 + Bortezomib DCGUD5Y Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Indazole derivative 5 + Bortezomib DCWKGJI Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Indazole derivative 5 + Bortezomib DCSGITM Indazole derivative 5 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Indazole derivative 5 + Bortezomib DCGJ4OW Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Indazole derivative 5 + Bortezomib DCQ43FU Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Indazole derivative 5 + Bortezomib DCT0GMC Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Indazole derivative 5 + Bortezomib DCONHZO Indazole derivative 5 Malignant melanoma (Cell Line: LOX IMVI) [6]
Itraconazole + Bortezomib DC84RIN Itraconazole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Ixabepilone + Bortezomib DCVJXOD Ixabepilone Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ixabepilone + Bortezomib DCZQ3A6 Ixabepilone Astrocytoma (Cell Line: SNB-19) [4]
Ixabepilone + Bortezomib DC0UU96 Ixabepilone Glioma (Cell Line: SF-268) [4]
Ixabepilone + Bortezomib DCBAAII Ixabepilone Renal cell carcinoma (Cell Line: SN12C) [4]
Ixabepilone + Bortezomib DC21UB4 Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Ixabepilone + Bortezomib DCP73XA Ixabepilone Carcinoma (Cell Line: RXF 393) [5]
Ixabepilone + Bortezomib DCOHFI6 Ixabepilone Lung adenocarcinoma (Cell Line: HOP-62) [6]
Ixabepilone + Bortezomib DC9WBWH Ixabepilone Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Ixabepilone + Bortezomib DCLU7NJ Ixabepilone Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Ixabepilone + Bortezomib DCGAFT0 Ixabepilone Melanoma (Cell Line: SK-MEL-2) [6]
Ixabepilone + Bortezomib DCB3MC6 Ixabepilone Prostate carcinoma (Cell Line: PC-3) [6]
JNK-IN-8 + Bortezomib DC77C9Q JNK-IN-8 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
JNK-IN-8 + Bortezomib DCKAULV JNK-IN-8 Astrocytoma (Cell Line: U251) [4]
JNK-IN-8 + Bortezomib DCGJYTS JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
JNK-IN-8 + Bortezomib DC6OBHX JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
JNK-IN-8 + Bortezomib DCZ5TDA JNK-IN-8 Glioma (Cell Line: SF-295) [4]
JNK-IN-8 + Bortezomib DCZI0IY JNK-IN-8 Colon adenocarcinoma (Cell Line: COLO 205) [5]
JNK-IN-8 + Bortezomib DC3POYU JNK-IN-8 Adenocarcinoma (Cell Line: DU-145) [6]
JNK-IN-8 + Bortezomib DCQMW2H JNK-IN-8 Adenocarcinoma (Cell Line: A549) [6]
JNK-IN-8 + Bortezomib DCVRC8X JNK-IN-8 Adenocarcinoma (Cell Line: HCT-15) [6]
JNK-IN-8 + Bortezomib DCTPJVR JNK-IN-8 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
JNK-IN-8 + Bortezomib DC5OOK2 JNK-IN-8 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
K-134 + Bortezomib DCFJAYH K-134 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
L-165041 + Bortezomib DCV9XKN L-165041 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Lapatinib + Bortezomib DCEKXFJ Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Lapatinib + Bortezomib DC5BCWW Lapatinib Breast carcinoma (Cell Line: KPL1) [5]
Lapatinib + Bortezomib DCCBYRL Lapatinib Carcinoma (Cell Line: EFM192B) [5]
Lapatinib + Bortezomib DCPQ4WH Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [5]
Lapatinib + Bortezomib DC868SC Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [5]
Lapatinib + Bortezomib DCYCMC5 Lapatinib Adenocarcinoma (Cell Line: CAOV3) [6]
Lapatinib + Bortezomib DCUT0M0 Lapatinib Adenocarcinoma (Cell Line: A427) [6]
Lapatinib + Bortezomib DCAFJA7 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [6]
Lapatinib + Bortezomib DCXV6RZ Lapatinib Adenocarcinoma (Cell Line: NCIH23) [6]
Lapatinib + Bortezomib DCD4WHQ Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [6]
Lapatinib + Bortezomib DC9ZHJO Lapatinib Adenocarcinoma (Cell Line: DLD1) [6]
Lapatinib + Bortezomib DCH6IMR Lapatinib Amelanotic melanoma (Cell Line: A2058) [6]
Lapatinib + Bortezomib DC9XUBG Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lapatinib + Bortezomib DCV7GWY Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [6]
Lapatinib + Bortezomib DCYYZKO Lapatinib Malignant melanoma (Cell Line: RPMI7951) [6]
Lapatinib + Bortezomib DC9C9OZ Lapatinib Malignant melanoma (Cell Line: SKMEL30) [6]
Lapatinib + Bortezomib DCHNND8 Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [6]
Lapatinib + Bortezomib DCFIHVI Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Lapatinib + Bortezomib DC7L6GU Lapatinib Prostate carcinoma (Cell Line: LNCAP) [6]
Lefaxin + Bortezomib DC45EUS Lefaxin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Lenalidomide + Bortezomib DC16SJH Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Bortezomib DCAYP7O Lenalidomide Malignant melanoma (Cell Line: UACC62) [6]
Lenalidomide + Bortezomib DCO8LF1 Lenalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Levamisole + Bortezomib DCYCGEZ Levamisole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
LIAROZOLE + Bortezomib DCKOMKB LIAROZOLE Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
LIAROZOLE + Bortezomib DC689XT LIAROZOLE Adenocarcinoma (Cell Line: SW-620) [6]
LIAROZOLE + Bortezomib DCLFDPC LIAROZOLE Malignant melanoma (Cell Line: UACC62) [6]
Lithium Citrate + Bortezomib DCV6FY1 Lithium Citrate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Loperamide + Bortezomib DC16U2V Loperamide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Lumefantrine + Bortezomib DCH6ONM Lumefantrine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Mechlorethamine + Bortezomib DCBQ3R5 Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Mechlorethamine + Bortezomib DCNU1X2 Mechlorethamine Astrocytoma (Cell Line: U251) [4]
Mechlorethamine + Bortezomib DC8KB9Q Mechlorethamine Glioma (Cell Line: SF-295) [4]
Mechlorethamine + Bortezomib DC1IS24 Mechlorethamine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Mechlorethamine + Bortezomib DCFGY0L Mechlorethamine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Mechlorethamine + Bortezomib DCOX9W2 Mechlorethamine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Mechlorethamine + Bortezomib DCUFOCE Mechlorethamine Adenocarcinoma (Cell Line: DU-145) [6]
Mechlorethamine + Bortezomib DC8UOMB Mechlorethamine Adenocarcinoma (Cell Line: A549) [6]
Mechlorethamine + Bortezomib DCK7ZKL Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Mechlorethamine + Bortezomib DCVET3F Mechlorethamine Melanoma (Cell Line: UACC-257) [6]
Mepacrine + Bortezomib DC9SGZP Mepacrine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Metformin + Bortezomib DC3M76V Metformin Amelanotic melanoma (Cell Line: A2058) [4]
Metformin + Bortezomib DCI23PH Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + Bortezomib DCLFJ1U Metformin Carcinoma (Cell Line: OV90) [5]
Methotrexate + Bortezomib DC8WDIW Methotrexate Malignant melanoma (Cell Line: A375) [4]
Methotrexate + Bortezomib DCYQ089 Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [5]
Miconazole + Bortezomib DC9OTR6 Miconazole Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Mitomycin + Bortezomib DC4KBL7 Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Mitomycin + Bortezomib DCX5TPY Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Mitomycin + Bortezomib DCEA8TE Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Mitomycin + Bortezomib DCHDJ85 Mitomycin Carcinoma (Cell Line: EFM192B) [5]
Mitomycin + Bortezomib DCW48UB Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [5]
Mitomycin + Bortezomib DC6Q9FU Mitomycin Adenocarcinoma (Cell Line: CAOV3) [6]
Mitomycin + Bortezomib DC2I58Y Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [6]
Mitomycin + Bortezomib DCMU880 Mitomycin Adenocarcinoma (Cell Line: A427) [6]
Mitomycin + Bortezomib DCQLDQ5 Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [6]
Mitomycin + Bortezomib DCDDJFT Mitomycin Adenocarcinoma (Cell Line: NCIH23) [6]
Mitomycin + Bortezomib DC4HLHP Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [6]
Mitomycin + Bortezomib DCNT3RI Mitomycin Adenocarcinoma (Cell Line: HT29) [6]
Mitomycin + Bortezomib DCBCTTI Mitomycin Adenocarcinoma (Cell Line: SW-620) [6]
Mitomycin + Bortezomib DCL649X Mitomycin Amelanotic melanoma (Cell Line: A2058) [6]
Mitomycin + Bortezomib DCOHYQM Mitomycin Germ cell tumour (Cell Line: PA1) [6]
Mitomycin + Bortezomib DCPVQJS Mitomycin Hodgkin lymphoma (Cell Line: L-1236) [6]
Mitomycin + Bortezomib DC2TSAU Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Mitomycin + Bortezomib DCDHLB6 Mitomycin Malignant melanoma (Cell Line: A375) [6]
Mitomycin + Bortezomib DCNT7UZ Mitomycin Mesothelioma (Cell Line: MSTO) [6]
Mitomycin + Bortezomib DC3DWSS Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Mitomycin + Bortezomib DCHZFOG Mitomycin Prostate carcinoma (Cell Line: LNCAP) [6]
MK-1775 + Bortezomib DC95KVY MK-1775 Adenocarcinoma (Cell Line: A427) [4]
MK-1775 + Bortezomib DCBLT1Y MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-1775 + Bortezomib DC55GOH MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-1775 + Bortezomib DCJH1GZ MK-1775 Adenocarcinoma (Cell Line: HT29) [4]
MK-1775 + Bortezomib DCZ7HEJ MK-1775 Adenocarcinoma (Cell Line: SW-620) [4]
MK-1775 + Bortezomib DCKAAZK MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
MK-1775 + Bortezomib DCF99WB MK-1775 Malignant melanoma (Cell Line: RPMI7951) [4]
MK-1775 + Bortezomib DCS42M7 MK-1775 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-1775 + Bortezomib DCNOE2F MK-1775 Malignant melanoma (Cell Line: UACC62) [4]
MK-1775 + Bortezomib DCT54QQ MK-1775 Mesothelioma (Cell Line: MSTO) [4]
MK-1775 + Bortezomib DCI9PTW MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-1775 + Bortezomib DCF09Z3 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-1775 + Bortezomib DCM5GJK MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
MK-1775 + Bortezomib DC4SF4C MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-1775 + Bortezomib DCMTJ7X MK-1775 Breast carcinoma (Cell Line: ZR751) [5]
MK-1775 + Bortezomib DCHJWN9 MK-1775 Breast carcinoma (Cell Line: OCUBM) [5]
MK-1775 + Bortezomib DCZG84X MK-1775 Carcinoma (Cell Line: EFM192B) [5]
MK-1775 + Bortezomib DCCJ2UW MK-1775 Carcinoma (Cell Line: MDAMB436) [5]
MK-1775 + Bortezomib DC4JPT4 MK-1775 Colon carcinoma (Cell Line: RKO) [5]
MK-2206 + Bortezomib DC41UO2 MK-2206 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-2206 + Bortezomib DC86BWE MK-2206 Adenocarcinoma (Cell Line: A427) [4]
MK-2206 + Bortezomib DCKLO65 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-2206 + Bortezomib DCAHG6J MK-2206 Adenocarcinoma (Cell Line: NCIH23) [4]
MK-2206 + Bortezomib DCZ3HNJ MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-2206 + Bortezomib DCQTQTB MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-2206 + Bortezomib DCD0ZHW MK-2206 Mesothelioma (Cell Line: MSTO) [4]
MK-2206 + Bortezomib DCTT52B MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-2206 + Bortezomib DCX3P0K MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-2206 + Bortezomib DCFBHCN MK-2206 Prostate carcinoma (Cell Line: LNCAP) [4]
MK-2206 + Bortezomib DC50KU0 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
MK-2206 + Bortezomib DCXFISR MK-2206 Breast carcinoma (Cell Line: KPL1) [5]
MK-2206 + Bortezomib DC47QAM MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [5]
MK-5108 + Bortezomib DCNFA39 MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
MK-5108 + Bortezomib DC382MM MK-5108 Colon carcinoma (Cell Line: RKO) [5]
MK-5108 + Bortezomib DCOWOUY MK-5108 Adenocarcinoma (Cell Line: CAOV3) [6]
MK-5108 + Bortezomib DCJEJ1U MK-5108 Malignant melanoma (Cell Line: RPMI7951) [6]
MK-5108 + Bortezomib DCVRUK2 MK-5108 Mesothelioma (Cell Line: MSTO) [6]
MK-5108 + Bortezomib DCB43QW MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Mycophenolic acid + Bortezomib DCP5MHP Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Nabilone + Bortezomib DCUPC5C Nabilone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Naltrexone + Bortezomib DCD004K Naltrexone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Nitisinone + Bortezomib DCZ15GN Nitisinone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Nizatidine + Bortezomib DCPTV0L Nizatidine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Pamidronate + Bortezomib DCPTOUY Pamidronate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
PD-0325901 + Bortezomib DC2MZ9T PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
PD-0325901 + Bortezomib DC88KZ8 PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
PD-0325901 + Bortezomib DCUI1S7 PD-0325901 Breast carcinoma (Cell Line: ZR751) [5]
PD-0325901 + Bortezomib DC5SK21 PD-0325901 Breast carcinoma (Cell Line: KPL1) [5]
PD-0325901 + Bortezomib DC6J6U9 PD-0325901 Carcinoma (Cell Line: EFM192B) [5]
PD-0325901 + Bortezomib DC9VRRN PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [5]
PD-0325901 + Bortezomib DCUMFU0 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [5]
PD-0325901 + Bortezomib DCNWPVH PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [6]
PD-0325901 + Bortezomib DCDZBJU PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [6]
PD-0325901 + Bortezomib DCD6TDK PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [6]
PD-0325901 + Bortezomib DCX8LC8 PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
PD-0325901 + Bortezomib DCGK8LO PD-0325901 Malignant melanoma (Cell Line: A375) [6]
PD-0325901 + Bortezomib DCGJTQ8 PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [6]
PD-0325901 + Bortezomib DCRAF8G PD-0325901 Mesothelioma (Cell Line: MSTO) [6]
PD-0325901 + Bortezomib DCXPSJ8 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
PD-0325901 + Bortezomib DCB7QI1 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [6]
Pelitinib + Bortezomib DC170M6 Pelitinib Hodgkin lymphoma (Cell Line: L-1236) [6]
Pentamidine + Bortezomib DC4YW0P Pentamidine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Pentostatin + Bortezomib DCJDJC0 Pentostatin Glioma (Cell Line: SF-268) [4]
Pentostatin + Bortezomib DCOPF29 Pentostatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PFK-158 + Bortezomib DCHBFD5 PFK-158 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Phenprocoumon + Bortezomib DC0Z9FZ Phenprocoumon Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Picoplatin + Bortezomib DCTR4HZ Picoplatin Astrocytoma (Cell Line: U251) [4]
Picoplatin + Bortezomib DCOB0KV Picoplatin Astrocytoma (Cell Line: SNB-19) [4]
Picoplatin + Bortezomib DC6GYWM Picoplatin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Picoplatin + Bortezomib DC9W9JD Picoplatin Glioblastoma (Cell Line: SNB-75) [4]
Picoplatin + Bortezomib DCGKAGZ Picoplatin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Picoplatin + Bortezomib DCA78QD Picoplatin Adenocarcinoma (Cell Line: NCIH23) [6]
Picoplatin + Bortezomib DCIGGUE Picoplatin Adenocarcinoma (Cell Line: A549) [6]
Picoplatin + Bortezomib DCES19B Picoplatin Adenocarcinoma (Cell Line: HCT-15) [6]
Picoplatin + Bortezomib DCHF2EG Picoplatin Adenocarcinoma (Cell Line: HCT116) [6]
Picoplatin + Bortezomib DCQLIRL Picoplatin Lung adenocarcinoma (Cell Line: HOP-62) [6]
Picoplatin + Bortezomib DC1XI6L Picoplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Picoplatin + Bortezomib DCWL1MF Picoplatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Plicamycin + Bortezomib DCR6T9R Plicamycin Astrocytoma (Cell Line: U251) [4]
Plicamycin + Bortezomib DCN8E08 Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Plicamycin + Bortezomib DC14RT2 Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Plicamycin + Bortezomib DCG1USW Plicamycin Adenocarcinoma (Cell Line: DU-145) [6]
Plicamycin + Bortezomib DCHR9MN Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [6]
Plicamycin + Bortezomib DCE5Z6G Plicamycin Adenocarcinoma (Cell Line: SW-620) [6]
Plicamycin + Bortezomib DCLC10A Plicamycin Amelanotic melanoma (Cell Line: M14) [6]
Plicamycin + Bortezomib DC0VHMX Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Plicamycin + Bortezomib DC7SM9T Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Plicamycin + Bortezomib DCKF1FL Plicamycin Malignant melanoma (Cell Line: UACC62) [6]
Plicamycin + Bortezomib DC7M49C Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Plicamycin + Bortezomib DC5H5T1 Plicamycin Melanoma (Cell Line: UACC-257) [6]
Plicamycin + Bortezomib DCEIC9S Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
PMID28460551-Compound-2 + Bortezomib DCZDIFO PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
PMID28460551-Compound-2 + Bortezomib DC5CCGF PMID28460551-Compound-2 Astrocytoma (Cell Line: U251) [4]
PMID28460551-Compound-2 + Bortezomib DCXBVDO PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
PMID28460551-Compound-2 + Bortezomib DCX8LG8 PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [5]
PMID28460551-Compound-2 + Bortezomib DCNOIUG PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [5]
PMID28460551-Compound-2 + Bortezomib DCBZTAI PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [5]
PMID28460551-Compound-2 + Bortezomib DC6X64P PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [5]
PMID28460551-Compound-2 + Bortezomib DCXO5W9 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [5]
PMID28460551-Compound-2 + Bortezomib DCLJSFC PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [5]
PMID28460551-Compound-2 + Bortezomib DCB1ZS4 PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [5]
PMID28460551-Compound-2 + Bortezomib DCEOETQ PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [5]
PMID28460551-Compound-2 + Bortezomib DCPAZD4 PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [5]
PMID28460551-Compound-2 + Bortezomib DCKJ95R PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [5]
PMID28460551-Compound-2 + Bortezomib DCK8TK8 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [6]
PMID28460551-Compound-2 + Bortezomib DCXCH1H PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [6]
PMID28460551-Compound-2 + Bortezomib DCAD5FS PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [6]
PMID28460551-Compound-2 + Bortezomib DCCHOZ4 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: A549) [6]
PMID28460551-Compound-2 + Bortezomib DC9TEN7 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [6]
PMID28460551-Compound-2 + Bortezomib DC9LR0T PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [6]
PMID28460551-Compound-2 + Bortezomib DCRCN16 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [6]
PMID28460551-Compound-2 + Bortezomib DCR9Q2H PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [6]
PMID28460551-Compound-2 + Bortezomib DCV23T3 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [6]
PMID28460551-Compound-2 + Bortezomib DCBR8M2 PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [6]
PMID28460551-Compound-2 + Bortezomib DCR8FZA PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
PMID28460551-Compound-2 + Bortezomib DCEHQ9T PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [6]
PMID28460551-Compound-2 + Bortezomib DC7XXQX PMID28460551-Compound-2 Malignant melanoma (Cell Line: HT144) [6]
PMID28460551-Compound-2 + Bortezomib DC1L6RJ PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [6]
PMID28460551-Compound-2 + Bortezomib DCHK1ZI PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [6]
PMID28460551-Compound-2 + Bortezomib DCOM8ID PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [6]
PMID28460551-Compound-2 + Bortezomib DC5WEU6 PMID28460551-Compound-2 Melanoma (Cell Line: MALME-3M) [6]
PMID28460551-Compound-2 + Bortezomib DC4XSS1 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [6]
PMID28460551-Compound-2 + Bortezomib DCKOXR9 PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [6]
PMID28460551-Compound-2 + Bortezomib DCGV0D7 PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
PMID28460551-Compound-2 + Bortezomib DCOALUY PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
PMID28460551-Compound-2 + Bortezomib DCRAVYP PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [6]
PMID28460551-Compound-2 + Bortezomib DCIHV3W PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [6]
PMID28870136-Compound-43 + Bortezomib DCN2S8A PMID28870136-Compound-43 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Pralatrexate + Bortezomib DCXFSXM Pralatrexate Anaplastic large cell lymphoma (Cell Line: SR) [4]
Pralatrexate + Bortezomib DCZRZKJ Pralatrexate Astrocytoma (Cell Line: U251) [4]
Pralatrexate + Bortezomib DC0GICH Pralatrexate Clear cell renal cell carcinoma (Cell Line: A498) [4]
Pralatrexate + Bortezomib DCMS7VU Pralatrexate Glioma (Cell Line: SF-295) [4]
Pralatrexate + Bortezomib DCTS7N2 Pralatrexate Invasive ductal carcinoma (Cell Line: BT-549) [5]
Pralatrexate + Bortezomib DCF2BZH Pralatrexate Adenocarcinoma (Cell Line: A549) [6]
Pralatrexate + Bortezomib DCZCSQQ Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Pralatrexate + Bortezomib DCWZDVL Pralatrexate Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Pralatrexate + Bortezomib DCXC87O Pralatrexate Prostate carcinoma (Cell Line: PC-3) [6]
Primidone + Bortezomib DCN56US Primidone Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Raloxifene + Bortezomib DCQ31GN Raloxifene Astrocytoma (Cell Line: SNB-19) [4]
Raloxifene + Bortezomib DC153OU Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [4]
Raloxifene + Bortezomib DCVRITC Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Raloxifene + Bortezomib DCV8AY3 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Raloxifene + Bortezomib DC52AQB Raloxifene Malignant melanoma (Cell Line: UACC62) [6]
Rifampin + Bortezomib DCQCG9J Rifampin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Romidepsin + Bortezomib DCB1DNY Romidepsin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Romidepsin + Bortezomib DC6DUEJ Romidepsin Adenocarcinoma (Cell Line: DU-145) [6]
Romidepsin + Bortezomib DCA0RV8 Romidepsin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Romidepsin + Bortezomib DCZJ5CC Romidepsin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Romidepsin + Bortezomib DCDQMQZ Romidepsin Malignant melanoma (Cell Line: UACC62) [6]
Romidepsin + Bortezomib DCBKFH3 Romidepsin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Ruxolitinib + Bortezomib DCN5ER0 Ruxolitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Ruxolitinib + Bortezomib DC7OJX6 Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Ruxolitinib + Bortezomib DCCJ07B Ruxolitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Ruxolitinib + Bortezomib DCVEI9Q Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Ruxolitinib + Bortezomib DCPLPH2 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Ruxolitinib + Bortezomib DCWRTNH Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Ruxolitinib + Bortezomib DCPCSS9 Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [6]
Ruxolitinib + Bortezomib DCKN1TP Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Sapanisertib + Bortezomib DCYZMHS Sapanisertib Hodgkin lymphoma (Cell Line: L-1236) [6]
SCH 727965 + Bortezomib DC8GWAA SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
SCH 727965 + Bortezomib DCB0I7O SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
SCH 727965 + Bortezomib DCS27DN SCH 727965 Breast carcinoma (Cell Line: KPL1) [5]
SCH 727965 + Bortezomib DCW3TTW SCH 727965 Breast carcinoma (Cell Line: OCUBM) [5]
SCH 727965 + Bortezomib DC0ZVQG SCH 727965 Carcinoma (Cell Line: OV90) [5]
SCH 727965 + Bortezomib DCBK9UI SCH 727965 Carcinoma (Cell Line: EFM192B) [5]
SCH 727965 + Bortezomib DCSAP4Q SCH 727965 Carcinoma (Cell Line: MDAMB436) [5]
SCH 727965 + Bortezomib DCQVGPL SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [5]
SCH 727965 + Bortezomib DCTATCF SCH 727965 Colon carcinoma (Cell Line: RKO) [5]
SCH 727965 + Bortezomib DCI1YZ7 SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [5]
SCH 727965 + Bortezomib DCAPM1C SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [6]
SCH 727965 + Bortezomib DCLFJL7 SCH 727965 Adenocarcinoma (Cell Line: A427) [6]
SCH 727965 + Bortezomib DCF5CU4 SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [6]
SCH 727965 + Bortezomib DCDJ1T7 SCH 727965 Adenocarcinoma (Cell Line: HT29) [6]
SCH 727965 + Bortezomib DCEPJYA SCH 727965 Adenocarcinoma (Cell Line: SW-620) [6]
SCH 727965 + Bortezomib DCXNNM6 SCH 727965 Amelanotic melanoma (Cell Line: A2058) [6]
SCH 727965 + Bortezomib DC5OS2F SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
SCH 727965 + Bortezomib DC7D6B0 SCH 727965 Malignant melanoma (Cell Line: A375) [6]
SCH 727965 + Bortezomib DCTCMHB SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [6]
SCH 727965 + Bortezomib DCLM3CF SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [6]
SCH 727965 + Bortezomib DCL0SP1 SCH 727965 Malignant melanoma (Cell Line: UACC62) [6]
SCH 727965 + Bortezomib DCCER6X SCH 727965 Mesothelioma (Cell Line: MSTO) [6]
SCH 727965 + Bortezomib DC513GB SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
SCH 727965 + Bortezomib DCW6RCC SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [6]
SCH 727965 + Bortezomib DC7BSAB SCH 727965 Prostate carcinoma (Cell Line: VCAP) [6]
Sirolimus + Bortezomib DC64R81 Sirolimus Glioma (Cell Line: SF-539) [4]
Sirolimus + Bortezomib DCWKHVR Sirolimus Colon adenocarcinoma (Cell Line: COLO 205) [5]
Sirolimus + Bortezomib DCQZA6K Sirolimus Adenocarcinoma (Cell Line: A549) [6]
Sirolimus + Bortezomib DC3RZWZ Sirolimus Adenocarcinoma (Cell Line: SW-620) [6]
Sirolimus + Bortezomib DC0INCX Sirolimus Adenocarcinoma (Cell Line: HCT116) [6]
Sirolimus + Bortezomib DCFE3Y9 Sirolimus Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Sirolimus + Bortezomib DC0QYOQ Sirolimus Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Sirolimus + Bortezomib DCZW8RL Sirolimus Melanoma (Cell Line: UACC-257) [6]
Sivelestat + Bortezomib DCF2H9A Sivelestat Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Sorafenib + Bortezomib DCNGUZO Sorafenib Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
SY-1425 + Bortezomib DC188M0 SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
SY-1425 + Bortezomib DCC9Y88 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Tacrolimus + Bortezomib DC8T6CI Tacrolimus Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Taxol + Bortezomib DC7SL8S Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Taxol + Bortezomib DCE44FL Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Taxol + Bortezomib DC0DK6F Taxol Glioma (Cell Line: SF-539) [4]
Taxol + Bortezomib DCCEEJG Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Taxol + Bortezomib DCSRTH4 Taxol Invasive ductal carcinoma (Cell Line: T-47D) [5]
Taxol + Bortezomib DCUKIE6 Taxol Rectal adenocarcinoma (Cell Line: SW837) [5]
Taxol + Bortezomib DCSVMCC Taxol Adenocarcinoma (Cell Line: CAOV3) [6]
Taxol + Bortezomib DCFL4MV Taxol Adenocarcinoma (Cell Line: OVCAR3) [6]
Taxol + Bortezomib DCBLM1A Taxol Adenocarcinoma (Cell Line: COLO320DM) [6]
Taxol + Bortezomib DCOY94A Taxol Adenocarcinoma (Cell Line: DLD1) [6]
Taxol + Bortezomib DCZ9NUM Taxol Adenocarcinoma (Cell Line: HCT-15) [6]
Taxol + Bortezomib DCT53UT Taxol Adenocarcinoma (Cell Line: HCT116) [6]
Taxol + Bortezomib DCAZMWN Taxol Amelanotic melanoma (Cell Line: A2058) [6]
Taxol + Bortezomib DCQJP5G Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Taxol + Bortezomib DCXTBX5 Taxol Malignant melanoma (Cell Line: RPMI7951) [6]
Taxol + Bortezomib DCRVTXY Taxol Mesothelioma (Cell Line: MSTO) [6]
Taxol + Bortezomib DCCI3IP Taxol Non small cell carcinoma (Cell Line: SKMES1) [6]
Taxol + Bortezomib DC1BZHL Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
TEM + Bortezomib DCOKGQH TEM Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Terazosin + Bortezomib DCGQG4W Terazosin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Testosterone cypionate + Bortezomib DCICHUV Testosterone cypionate Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Tetracycline + Bortezomib DCNE1U0 Tetracycline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Theophylline + Bortezomib DCLPNJ5 Theophylline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Thioguanine + Bortezomib DC5DXG5 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Thioguanine + Bortezomib DCB2TTK Thioguanine Glioma (Cell Line: SF-295) [4]
Thioguanine + Bortezomib DCPPBWV Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [5]
Thioguanine + Bortezomib DC9U5WT Thioguanine Adenocarcinoma (Cell Line: DU-145) [6]
Thioguanine + Bortezomib DCMHTLC Thioguanine Adenocarcinoma (Cell Line: A549) [6]
Thioguanine + Bortezomib DC80N9N Thioguanine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Thioguanine + Bortezomib DCIUQ15 Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Topetecan + Bortezomib DCVYVBV Topetecan Chronic myelogenous leukemia (Cell Line: K-562) [4]
Topetecan + Bortezomib DCXJB3T Topetecan Amelanotic melanoma (Cell Line: M14) [6]
Topetecan + Bortezomib DC8C41J Topetecan Lung adenocarcinoma (Cell Line: HOP-62) [6]
Topotecan + Bortezomib DC9EVWI Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Topotecan + Bortezomib DCY4X66 Topotecan Carcinoma (Cell Line: MCF7) [5]
Topotecan + Bortezomib DCKGA0N Topotecan Colon carcinoma (Cell Line: RKO) [5]
Topotecan + Bortezomib DCY580X Topotecan Adenocarcinoma (Cell Line: NCIH2122) [6]
Topotecan + Bortezomib DCQVTOR Topotecan Adenocarcinoma (Cell Line: NCIH520) [6]
Topotecan + Bortezomib DCF95N8 Topotecan Adenocarcinoma (Cell Line: A549) [6]
Topotecan + Bortezomib DCU231E Topotecan Adenocarcinoma (Cell Line: COLO320DM) [6]
Topotecan + Bortezomib DCVOLY2 Topotecan Adenocarcinoma (Cell Line: HCT116) [6]
Topotecan + Bortezomib DCTREM8 Topotecan Adenocarcinoma (Cell Line: HT29) [6]
Topotecan + Bortezomib DC7F2JG Topotecan Adenocarcinoma (Cell Line: SW-620) [6]
Topotecan + Bortezomib DC5P6PH Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Topotecan + Bortezomib DC9695D Topotecan Astrocytoma (Cell Line: SNB-19) [6]
Topotecan + Bortezomib DCXC3DR Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Topotecan + Bortezomib DCV009E Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [6]
Topotecan + Bortezomib DCIE4R7 Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Topotecan + Bortezomib DCI6I4M Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [6]
Topotecan + Bortezomib DCLSJ1J Topotecan Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Topotecan + Bortezomib DCYFPNC Topotecan Mesothelioma (Cell Line: MSTO) [6]
Topotecan + Bortezomib DCB8ZSS Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Topotecan + Bortezomib DCKCUV2 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Topotecan + Bortezomib DCMF6XI Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Topotecan + Bortezomib DCM50XU Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Topotecan + Bortezomib DCH6QET Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [6]
Topotecan + Bortezomib DCCC5TI Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Topotecan + Bortezomib DCPTDDF Topotecan Prostate carcinoma (Cell Line: LNCAP) [6]
Topotecan + Bortezomib DC5JVGV Topotecan Prostate carcinoma (Cell Line: PC-3) [6]
Tranexamic acid + Bortezomib DCZB26W Tranexamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Triapine + Bortezomib DCJ3DEQ Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [6]
Triapine + Bortezomib DCXJV70 Triapine Clear cell renal cell carcinoma (Cell Line: 786-0) [6]
Triflupromazine + Bortezomib DC1PNUU Triflupromazine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Trifluridine + Bortezomib DCLHEGY Trifluridine Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Trifluridine + Bortezomib DC4DYWC Trifluridine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Trifluridine + Bortezomib DCMMI8M Trifluridine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Trifluridine + Bortezomib DC9YYLJ Trifluridine Carcinoma (Cell Line: MCF7) [5]
Trifluridine + Bortezomib DC8DYUM Trifluridine Adenocarcinoma (Cell Line: OVCAR3) [6]
Trifluridine + Bortezomib DCVP6WQ Trifluridine Adenocarcinoma (Cell Line: HT29) [6]
Trifluridine + Bortezomib DC1W423 Trifluridine Adenocarcinoma (Cell Line: HCT-15) [6]
Trifluridine + Bortezomib DCSGO5M Trifluridine Adenocarcinoma (Cell Line: HCC-2998) [6]
Trifluridine + Bortezomib DCARFOE Trifluridine Amelanotic melanoma (Cell Line: M14) [6]
Trifluridine + Bortezomib DC4PO0Q Trifluridine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Trifluridine + Bortezomib DCQWZY4 Trifluridine Malignant melanoma (Cell Line: LOX IMVI) [6]
Trifluridine + Bortezomib DCH1QH3 Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Trifluridine + Bortezomib DCR0TWN Trifluridine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Trihexyphenidyl + Bortezomib DCOW4WO Trihexyphenidyl Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Trioxsalen + Bortezomib DC7KT5P Trioxsalen Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Uracil mustard + Bortezomib DC1HU3P Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Uracil mustard + Bortezomib DCF7AQT Uracil mustard Astrocytoma (Cell Line: U251) [4]
Uracil mustard + Bortezomib DC1KJMN Uracil mustard Chronic myelogenous leukemia (Cell Line: K-562) [4]
Uracil mustard + Bortezomib DCTFFLN Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Uracil mustard + Bortezomib DCW71UK Uracil mustard Colon adenocarcinoma (Cell Line: COLO 205) [5]
Uracil mustard + Bortezomib DC6R9GE Uracil mustard Adenocarcinoma (Cell Line: A549) [6]
Uracil mustard + Bortezomib DCINXZL Uracil mustard Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Uracil mustard + Bortezomib DCHD6KO Uracil mustard Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Valproic Acid + Bortezomib DC1CSSX Valproic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Valrubicin + Bortezomib DCYKNJB Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Valrubicin + Bortezomib DCBDV81 Valrubicin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Valrubicin + Bortezomib DCE9L0Y Valrubicin Astrocytoma (Cell Line: U251) [4]
Valrubicin + Bortezomib DC6M9NP Valrubicin Astrocytoma (Cell Line: SNB-19) [4]
Valrubicin + Bortezomib DC7U5GE Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Valrubicin + Bortezomib DCU9JQ7 Valrubicin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Valrubicin + Bortezomib DC05GWW Valrubicin Glioma (Cell Line: SF-295) [4]
Valrubicin + Bortezomib DCJ40VR Valrubicin Glioma (Cell Line: SF-539) [4]
Valrubicin + Bortezomib DCRF5GE Valrubicin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Valrubicin + Bortezomib DCBRJRH Valrubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Valrubicin + Bortezomib DC85PNM Valrubicin Colon carcinoma (Cell Line: KM12) [5]
Valrubicin + Bortezomib DC6BO7J Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Valrubicin + Bortezomib DC95D20 Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Valrubicin + Bortezomib DCLKRKP Valrubicin Adenocarcinoma (Cell Line: DU-145) [6]
Valrubicin + Bortezomib DC1P0TM Valrubicin Adenocarcinoma (Cell Line: SW-620) [6]
Valrubicin + Bortezomib DCZ8VF0 Valrubicin Adenocarcinoma (Cell Line: HCC-2998) [6]
Valrubicin + Bortezomib DCOHIZJ Valrubicin Adenocarcinoma (Cell Line: HCT-15) [6]
Valrubicin + Bortezomib DCHCI3A Valrubicin Adenocarcinoma (Cell Line: HT29) [6]
Valrubicin + Bortezomib DCHMNKR Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Valrubicin + Bortezomib DCWVYIA Valrubicin Amelanotic melanoma (Cell Line: M14) [6]
Valrubicin + Bortezomib DC3AL94 Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Valrubicin + Bortezomib DCFJLST Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Valrubicin + Bortezomib DCGHSXL Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Valrubicin + Bortezomib DC7NKYE Valrubicin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Valrubicin + Bortezomib DCUI03M Valrubicin Malignant melanoma (Cell Line: LOX IMVI) [6]
Valrubicin + Bortezomib DCIJG5N Valrubicin Malignant melanoma (Cell Line: UACC62) [6]
Valrubicin + Bortezomib DCEZVDT Valrubicin Melanoma (Cell Line: UACC-257) [6]
Valrubicin + Bortezomib DCR8B0L Valrubicin Melanoma (Cell Line: MALME-3M) [6]
Vandetanib + Bortezomib DCWNKD6 Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vandetanib + Bortezomib DC54JQD Vandetanib Adenocarcinoma (Cell Line: HT29) [6]
Vandetanib + Bortezomib DCN1TTG Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Vandetanib + Bortezomib DCNCCXB Vandetanib Amelanotic melanoma (Cell Line: M14) [6]
Vandetanib + Bortezomib DCF6H71 Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vandetanib + Bortezomib DCKOB5V Vandetanib Melanoma (Cell Line: SK-MEL-2) [6]
Vemurafenib + Bortezomib DCJY4UD Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Vemurafenib + Bortezomib DCJ82I9 Vemurafenib Carcinoma (Cell Line: RXF 393) [5]
Vemurafenib + Bortezomib DCXDE73 Vemurafenib Carcinoma (Cell Line: MCF7) [5]
Vemurafenib + Bortezomib DCJT2HF Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vemurafenib + Bortezomib DCHN6WG Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Vemurafenib + Bortezomib DC37G36 Vemurafenib Adenocarcinoma (Cell Line: HT29) [6]
Vemurafenib + Bortezomib DCDKMLJ Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [6]
Vemurafenib + Bortezomib DC1V05R Vemurafenib Anaplastic large cell lymphoma (Cell Line: SR) [6]
Vemurafenib + Bortezomib DCB13M2 Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [6]
Vemurafenib + Bortezomib DCRSKA7 Vemurafenib Glioblastoma (Cell Line: SNB-75) [6]
Vemurafenib + Bortezomib DCXOPIA Vemurafenib Malignant melanoma (Cell Line: UACC62) [6]
Vemurafenib + Bortezomib DC2C8W6 Vemurafenib Melanoma (Cell Line: MALME-3M) [6]
Vinblastine + Bortezomib DCADVMS Vinblastine Adenocarcinoma (Cell Line: CAOV3) [4]
Vinblastine + Bortezomib DCGBQVB Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [4]
Vinblastine + Bortezomib DC015V8 Vinblastine Adenocarcinoma (Cell Line: NCIH520) [4]
Vinblastine + Bortezomib DCXRVKB Vinblastine Adenocarcinoma (Cell Line: HT29) [4]
Vinblastine + Bortezomib DC135RB Vinblastine Amelanotic melanoma (Cell Line: A2058) [4]
Vinblastine + Bortezomib DCA4DKX Vinblastine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Vinblastine + Bortezomib DCTJA8M Vinblastine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vinblastine + Bortezomib DCJR9F8 Vinblastine Malignant melanoma (Cell Line: RPMI7951) [4]
Vinblastine + Bortezomib DCNNFBA Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vinblastine + Bortezomib DCWUG6L Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Vinblastine + Bortezomib DCA1AB7 Vinblastine Carcinoma (Cell Line: MDAMB436) [5]
Vinblastine + Bortezomib DC1YHCD Vinblastine Colon adenocarcinoma (Cell Line: LOVO) [5]
Vinblastine + Bortezomib DCS6EZ3 Vinblastine Colon carcinoma (Cell Line: RKO) [5]
Vinblastine + Bortezomib DCNTM39 Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [5]
Vincristine + Bortezomib DC0C2CN Vincristine Hodgkin lymphoma (Cell Line: L-1236) [4]
Vinflunine + Bortezomib DCLQ49N Vinflunine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vinflunine + Bortezomib DC0LM75 Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [6]
Vinorelbine + Bortezomib DC1U6MY Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Vinorelbine + Bortezomib DC91ZPZ Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [6]
Vinorelbine + Bortezomib DC5Z0QB Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [6]
Vinorelbine + Bortezomib DCP2R0W Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Vinorelbine + Bortezomib DCBGZA4 Vinorelbine Malignant melanoma (Cell Line: RPMI7951) [6]
Vinorelbine + Bortezomib DC3BK7R Vinorelbine Mesothelioma (Cell Line: MSTO) [6]
Vinorelbine + Bortezomib DC7C8PQ Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [6]
Vinorelbine + Bortezomib DCAB231 Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [6]
Vismodegib + Bortezomib DCCXEUP Vismodegib Carcinoma (Cell Line: MCF7) [5]
Vismodegib + Bortezomib DCK9GF2 Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vismodegib + Bortezomib DCG27A8 Vismodegib Adenocarcinoma (Cell Line: HT29) [6]
Vismodegib + Bortezomib DCMRP3B Vismodegib Adenocarcinoma (Cell Line: HCT116) [6]
Vismodegib + Bortezomib DCQ9YQD Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [6]
Vismodegib + Bortezomib DCGBEL0 Vismodegib Amelanotic melanoma (Cell Line: M14) [6]
Vismodegib + Bortezomib DC4Z185 Vismodegib Anaplastic large cell lymphoma (Cell Line: SR) [6]
Vismodegib + Bortezomib DC6V19B Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [6]
Vismodegib + Bortezomib DC8TMOZ Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Vismodegib + Bortezomib DC6YRE5 Vismodegib Glioblastoma (Cell Line: SNB-75) [6]
Vismodegib + Bortezomib DCRZPZ5 Vismodegib Malignant melanoma (Cell Line: UACC62) [6]
Vismodegib + Bortezomib DCN7Q5N Vismodegib Melanoma (Cell Line: SK-MEL-2) [6]
Zaleplon + Bortezomib DC7CU97 Zaleplon Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1114 DrugCom(s)
70 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Belinostat + Bortezomib DC8WIEL Belinostat Acute Lymphocytic Leukemia [7]
Belinostat + Bortezomib DCFQALZ Belinostat Adult Grade III Lymphomatoid Granulomatosis [8]
Bendamustine hydrochloride + Bortezomib DC5D3DA Bendamustine hydrochloride Lymphoma [9]
Bortezomib + Romidepsin DC0H84Q Romidepsin Leukemia [10]
Bortezomib + Irinotecan DC0P7AH Irinotecan Adenocarcinoma of the Gastroesophageal Junction [11]
Bortezomib + Interferon alfa-2B DC1H6I8 Interferon alfa-2B Melanoma [12]
Bortezomib + Doxorubicin DC2Q6F4 Doxorubicin Multiple Myeloma [13]
Bortezomib + Romidepsin DC31YGY Romidepsin Multiple Myeloma [14]
Bortezomib + Hydroxychloroquine DC41Z69 Hydroxychloroquine Multiple Myeloma and Plasma Cell Neoplasm [15]
Bortezomib + Vorinostat DC9QK1T Vorinostat Multiple Myeloma [16]
Bortezomib + Decitabine DCA9OFS Decitabine Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities [17]
Bortezomib + Irinotecan DCCF8S8 Irinotecan Recurrent Squamous Cell Carcinoma of the Hypopharynx [18]
Bortezomib + Vandetanib DCFX0HE Vandetanib Medullary Thyroid Carcinoma [19]
Bortezomib + Perifosine DCJ3MVB Perifosine Multiple Myeloma [20]
Bortezomib + Temsirolimus DCM5FIW Temsirolimus Multiple Myeloma [21]
Bortezomib + Fludarabine DCSEHGD Fludarabine Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue [22]
Bortezomib + Busulfan DCTBJYN Busulfan Multiple Myeloma [23]
Bortezomib + Oxaliplatin DCTXCEE Oxaliplatin Unspecified Adult Solid Tumor, Protocol Specific [24]
Bortezomib + Azacitidine DCVI4CO Azacitidine Adult Nasal Type Extranodal NK/T-cell Lymphoma [25]
Bortezomib + Azacitidine DCWTM2A Azacitidine Leukemia [26]
Bortezomib + Sirolimus DC9EWP3 Sirolimus Autologous Hematopoietic Stem Cell Transplant Recipient [27]
Bortezomib + Ibrutinib DCZ3JDZ Ibrutinib Mantle Cell Lymphoma [28]
Dexamethasone + Bortezomib DC1SGGR Dexamethasone Multiple Myeloma [20]
Dexamethasone + Bortezomib DCA09QP Dexamethasone Multiple Myeloma [29]
Dexamethasone + Bortezomib DC6B7B1 Dexamethasone Multiple Myeloma [30]
Dexamethasone + Bortezomib DCQ1M1S Dexamethasone Refractory Multiple Myeloma [31]
Dexamethasone + Bortezomib DCVMOZF Dexamethasone Multiple Myeloma [32]
Docetaxel + Bortezomib DC8AWAI Docetaxel Lung Cancer [33]
Docetaxel + Bortezomib DCUJT3P Docetaxel Adenocarcinoma of the Lung [34]
Duvelisib + Bortezomib DCUJJLM Duvelisib Lymphoma [35]
Eflornithine + Bortezomib DC4MD8M Eflornithine Neuroblastoma Recurrent [36]
Everolimus + Bortezomib DC0BKSC Everolimus 714leukemia [37]
Fulvestrant + Bortezomib DC4REU9 Fulvestrant Metastatic Breast Carcinoma [38]
Idarubicin + Bortezomib DCSJ8O5 Idarubicin Acute Myelogenous Leukemia [39]
Lenalidomide + Bortezomib DCPAUOT Lenalidomide Refractory Multiple Myeloma [40]
Lenalidomide + Bortezomib DC6ELTN Lenalidomide Myelodysplasia [41]
Methotrexate + Bortezomib DC0MTOY Methotrexate Graft Versus Host Disease [42]
Methotrexate + Bortezomib DCEQO1B Methotrexate Hematologic Malignancies [43]
Midostaurin + Bortezomib DC0QYJM Midostaurin Acute Myeloid Leukemia [44]
Napabucasin + Bortezomib DCXG9QI Napabucasin Hematologic Malignancy [45]
Paclitaxel + Bortezomib DCGF04P Paclitaxel Unspecified Adult Solid Tumor, Protocol Specific [46]
Panobinostat + Bortezomib DC5GGHB Panobinostat Mantle Cell Lymphoma [47]
Panobinostat + Bortezomib DC5V1H3 Panobinostat Multiple Myeloma [48]
Plerixafor + Bortezomib DCK18D9 Plerixafor Multiple Myeloma [49]
Pravastatin + Bortezomib DCOW9GD Pravastatin Leukemia [50]
Ruxolitinib + Bortezomib DC8Q12Q Ruxolitinib Hodgkin's Lymphoma [51]
Tanespimycin + Bortezomib DC33OQI Tanespimycin Adult Acute Basophilic Leukemia [52]
Tanespimycin + Bortezomib DCQQSXX Tanespimycin Adult Grade III Lymphomatoid Granulomatosis [53]
Temozolomide + Bortezomib DC9987E Temozolomide Brain and Central Nervous System Tumors [54]
Zarnestra + Bortezomib DC94YG5 Zarnestra Multiple Myeloma [55]
Zarnestra + Bortezomib DCI49ZU Zarnestra Refractory Multiple Myeloma [56]
Zidovudine + Bortezomib DC15WZD Zidovudine Lymphoproliferative Disorder [57]
Bortezomib + Tacrolimus DC5I8Y5 Tacrolimus Acute Leukemia [58]
Bortezomib + Aciclovir DCLECW6 Aciclovir Non-Small Cell Lung Cancer [59]
Cyclophosphamide + Bortezomib DCHT595 Cyclophosphamide Adult-onset Immunodeficiency [60]
Dexamethasone + Bortezomib DC51QO5 Dexamethasone Multiple Myeloma [61]
Dexamethasone + Bortezomib DCP0GBM Dexamethasone Relapsed or Refractory Multiple Myeloma [62]
Dexamethasone + Bortezomib DCUKT0G Dexamethasone Multiple Myeloma [63]
Dexamethasone + Bortezomib DC1P7A2 Dexamethasone Lymphoma [64]
Dexamethasone + Bortezomib DC2UGER Dexamethasone Multiple Myeloma [65]
Etoposide + Bortezomib DCM9986 Etoposide Adult Acute Monoblastic Leukemia (M5a) [66]
Idarubicin + Bortezomib DC09IXG Idarubicin Adult Acute Monoblastic Leukemia (M5a) [66]
Ifosfamide + Bortezomib DCG2D6V Ifosfamide Adult Lymphocyte Depletion Hodgkin Lymphoma [67]
LDE225 + Bortezomib DC8ASPV LDE225 Multiple Myeloma [68]
Methotrexate + Bortezomib DCJI1O7 Methotrexate Leukemia [69]
Mycophenolate mofetil + Bortezomib DC65YAN Mycophenolate mofetil Lung Diseases, Interstitial [70]
Venetoclax + Bortezomib DC48LQA Venetoclax High Grade B-Cell Lymphoma, Not Otherwise Specified [71]
Dexamethasone + Bortezomib DC4DYZA Dexamethasone Multiple Myeloma [72]
Dexamethasone + Bortezomib DC8SOTE Dexamethasone Multiple Myeloma [73]
Dexamethasone + Bortezomib DCPG97F Dexamethasone Multiple Myeloma [74]
------------------------------------------------------------------------------------
⏷ Show the Full List of 70 DrugCom(s)

References

1 Bortezomib FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
7 ClinicalTrials.gov (NCT01075425) Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
8 ClinicalTrials.gov (NCT00348985) PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
9 ClinicalTrials.gov (NCT01415752) Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
10 ClinicalTrials.gov (NCT00963274) Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
11 ClinicalTrials.gov (NCT00061932) Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
12 ClinicalTrials.gov (NCT01462773) Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
13 ClinicalTrials.gov (NCT00103506) Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
14 ClinicalTrials.gov (NCT00765102) Trial of Romidepsin and Bortezomib for Multiple Myeloma
15 ClinicalTrials.gov (NCT00568880) Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
16 ClinicalTrials.gov (NCT00111813) Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
17 ClinicalTrials.gov (NCT00703300) Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
18 ClinicalTrials.gov (NCT00103259) Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
19 ClinicalTrials.gov (NCT00923247) A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
20 ClinicalTrials.gov (NCT00401011) Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
21 ClinicalTrials.gov (NCT00483262) Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
22 ClinicalTrials.gov (NCT00068315) Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
23 ClinicalTrials.gov (NCT01009840) IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
24 ClinicalTrials.gov (NCT00066625) Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
25 ClinicalTrials.gov (NCT01129180) Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
26 ClinicalTrials.gov (NCT00624936) Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
27 ClinicalTrials.gov (NCT01163357) Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
28 ClinicalTrials.gov (NCT02356458) Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
29 ClinicalTrials.gov (NCT00335348) Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
30 ClinicalTrials.gov (NCT01497093) Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
31 ClinicalTrials.gov (NCT01212952) Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
32 ClinicalTrials.gov (NCT00560352) Safety Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone for Multiple Myeloma
33 ClinicalTrials.gov (NCT00064012) Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
34 ClinicalTrials.gov (NCT00118183) Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
35 ClinicalTrials.gov (NCT02783625) Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
36 ClinicalTrials.gov (NCT02139397) Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
37 ClinicalTrials.gov (NCT00671112) Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
38 ClinicalTrials.gov (NCT01142401) Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
39 ClinicalTrials.gov (NCT00382954) Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
40 ClinicalTrials.gov (NCT00153933) Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
41 ClinicalTrials.gov (NCT00580242) A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
42 ClinicalTrials.gov (NCT01754389) Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
43 ClinicalTrials.gov (NCT00369226) Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
44 ClinicalTrials.gov (NCT01174888) Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
45 ClinicalTrials.gov (NCT02352558) A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
46 ClinicalTrials.gov (NCT00030368) Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
47 ClinicalTrials.gov (NCT01504776) Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
48 ClinicalTrials.gov (NCT00891033) Panobinostat/Velcade in Multiple Myeloma
49 ClinicalTrials.gov (NCT00903968) Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
50 ClinicalTrials.gov (NCT02484261) Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
51 ClinicalTrials.gov (NCT02613598) Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
52 ClinicalTrials.gov (NCT00103272) 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
53 ClinicalTrials.gov (NCT00096005) Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
54 ClinicalTrials.gov (NCT00512798) Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
55 ClinicalTrials.gov (NCT00361088) A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
56 ClinicalTrials.gov (NCT00243035) Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
57 ClinicalTrials.gov (NCT00092222) Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
58 ClinicalTrials.gov (NCT02877082) Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
59 ClinicalTrials.gov (NCT01833143) Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
60 ClinicalTrials.gov (NCT03103555) Treatment of Adult-Onset Immunodeficiency With Bortezomib
61 ClinicalTrials.gov (NCT02902965) Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
62 ClinicalTrials.gov (NCT00773838) Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
63 ClinicalTrials.gov (NCT05432414) PVd Versus Vd in NDMM Patients With RI
64 ClinicalTrials.gov (NCT00740415) Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
65 ClinicalTrials.gov (NCT01056276) Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
66 ClinicalTrials.gov (NCT00666588) Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
67 ClinicalTrials.gov (NCT00381940) Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
68 ClinicalTrials.gov (NCT02254551) Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
69 ClinicalTrials.gov (NCT01323920) Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
70 ClinicalTrials.gov (NCT02370693) Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
71 ClinicalTrials.gov (NCT04285268) Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
72 ClinicalTrials.gov (NCT01470131) A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
73 ClinicalTrials.gov (NCT01002248) Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
74 ClinicalTrials.gov (NCT01734928) Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma